• Psychedelic Medicine

Women's Health | +70 articles

psychedelic%20drugs%20medical%20treatment%2088.jpg



The new, non-invasive cervical pre-cancer test that's easily done at home*

Medical Xpress | Nov 4 2019

Researchers have developed a non-invasive test to detect cervical pre-cancer by analysing urine and vaginal samples collected by the women themselves.

In a presentation at the 2019 NCRI Cancer Conference, Dr. Belinda Nedjai said that self-sampling test had proved popular with women taking part in the study and this meant that it was likely to improve participation in cervical cancer screening programmes.

"The initial use of self-sampling is likely to be for women who do not attend clinic after a screening invitation and countries without a cervical cancer screening programme. In the longer term, self-sampling could become the standard method for all screening tests. The study indicated that women much preferred doing a test at home than attending a doctor's surgery," said Dr. Nedjai, who is Senior Research Fellow and Director of the Molecular Epidemiology Lab at Queen Mary University of London, UK.

"To the best of our knowledge, this study is the largest to test a methylation classifier, called S5, in urine and self-collected cervical samples to detect pre-cancer lesions in women who have been referred for further investigation. We expect the self-sampling test to improve acceptance rates for cervical cancer screening, as well as reducing costs to health services and improving the performance of screening programmes."

The current gold-standard pap smear test is taken in the clinic and often follows a positive test for the human papilloma virus (HPV).

Dr. Nedjai said: "HPV testing is rapidly becoming the primary screening method for cervical cancer worldwide. It is a very sensitive method, very good at detecting true positives, but lacks specificity—in other words, a second test is needed to exclude HPV positive women that are not at increased risk of developing cancer. The choice of an appropriate strategy for high-risk HPV positive women is a key issue."

The S5 test developed by Dr. Nedjai and her colleagues at Queen Mary, measures DNA methylation—a chemical change to one of the four DNA base letters that make up the human genetic code. S5 looks at DNA methylation of four HPV types most strongly associated with cancer to produce a score that indicates the level of risk. If the score is above a selected cut-off it indicates an increased risk of a pre-cancer lesion, and the higher the score the higher the risk of cancer. They had discovered in earlier research that when S5 was used on cervical samples, it was 100% accurate at detecting invasive cervical cancer, and 93% accurate at detecting pre-cancer in women who had an HPV positive test.

Cervical cancer is preceded by the abnormal growth of precursor cells on the surface of the cervix—so called cervical intraepithelial neoplasia (CIN) or pre-cancer—that can develop into cervical cancer. It is divided into three stages (CIN1, CIN2 and CIN3), with the likelihood of the cells developing into cancer increasing at each stage.

"We decided to assess whether S5 could identify women who had CIN3 pre-cancer lesions using urine and vaginal samples," said Dr. Nedjai.

Women attending the colposcopy clinic at the Royal London Hospital as a consequence of an abnormal smear test or positive HPV result were asked to take part in a study led by Professor Jack Cuzick, Director of the Wolfson Institute of Preventive Medicine at Queen Mary. A total of 620 women provided vaginal samples, collected themselves using vaginal swabs, and 503 of these women also provided a urine sample. The researchers extracted and analysed the DNA in the lab and generated S5 scores.

"We found that S5 classifier with or without HPV testing worked well in both urine and vaginal samples," said Dr. Nedjai. "It distinguished between women who had no pre-cancerous lesions and those who had CIN3 or higher lesions. We evaluated two distinct ways that S5 could be used. We first tested S5 as a secondary test on HPV positive women to limit the number of patients sent to colposcopy. In urine, S5 was better at correctly identifying women who did have pre-cancer lesions than testing for the presence of HPV16 or 18; 96% of true CIN3 were identified with S5 compared to 73% with an HPV16 or 18 test. Secondly, we evaluated S5 as a standalone test, without first doing HPV testing. We adjusted the cut-offs to identify at least 85% of true positives. Urine performed as well as self-collected vaginal samples."

"We are currently working on new markers to try to improve the accuracy of the classifier even further, but these findings represent an advance in cervical cancer screening, especially for women who do not attend the clinic, such as older women, or women who find the smear test too painful or who do not have access to a screening programme in their country. We think it's promising."


In the future, Dr. Nedjai said the samples could be collected at home for both HPV and methylation analysis without the need to go to the clinic.

Dr. Manuel Rodriguez-Justo is a consultant pathologist at University College London (UK) and a member of the NCRI's sub-committee on early detection and prevention. He was not involved with the research. He commented: "This is exciting research that shows it's possible to detect cervical pre-cancer that is at high risk of developing into invasive cancer in urine and vaginal samples collected by women in the comfort and privacy of their own homes. This has the potential to revolutionise the way a positive HPV test is followed up, as well as making it easier for women in countries with no cervical cancer screening programme to be tested."

"The cervical screening programme in the UK has been very successful but there has been also a decline in its uptake, particularly in some areas in the UK and specific ethnic groups. If the results of this study are validated by other groups, the implementation of urine-based testing and self-sampled vaginal samples will, potentially, increase uptake and reduce costs for the screening programmes whilst achieving high sensitivity to detect pre-malignant lesions."


Cervical cancer is the fourth most frequently occurring cancer in women in the world. In 2018, there were an estimated 570,000 new cases of cervical cancer and 310,000 women died from the disease. Infection with HPV is almost the main cause of cervical cancer. More than 25 different types of HPV are transmitted through sexual contact and 12 of them carry a high risk of triggering the development of cancer cells by inactivating tumour suppressor proteins

*From the article here:
 
Last edited:
Psychedelics_Postpartum-1370x1536.jpg


Can psychedelics help Postpartum Depression?

by Katie Stone & Medical Editor: Dr. Benjamin Malcolm, PharmD, MPH, BCPP | Psychable

The months and years following pregnancy and childbirth are a tender time for everyone involved. Human cultures throughout the world have revered the months following birth, honoring the mother with ceremony, and setting up crucial community and family support networks to offer the mother and father time to adjust, heal, and recover.

Modern U.S. culture, in contrast, is less supportive. As a nation, we may pay a significant price in maternal and child health because of it. While psychedelic research had tended to focus on end-of-life anxiety, post-traumatic stress disorder (PTSD), treatment-resistant depression, and substance use disorders, is it reasonable to think they could help with postpartum depression also?

Before we dive into the discussion involving psychedelics and postpartum depression, let’s review a little more about this maternal health condition.

Postpartum Mental Health in the US Today

Postpartum depression impacts an estimated 1 out of 8 mothers annually in the United States. Mothers are more at risk for postpartum depression, but postpartum does not impact mothers alone.

Most obstetricians and gynecologists are not trained to offer the specific mental health support that pregnant and new mothers need, and less than 20% of people experiencing postpartum depression seek help. While it is standard practice to provide questionnaires assessing possible symptoms of postpartum depression during pregnancy and post-birth recovery, there is an urgent need for a more proactive approach to diagnosing and treating this condition.

What is Postpartum Depression?

Postpartum depression is a potentially serious mental health condition classified by debilitating depression following childbirth. It affects 10%-20% of new mothers and can cause long-term health impacts if not treated. Sudden shifts in hormones, adjustment to a new role as a parent, and disrupted sleep are just a few of the many stress factors that can underlie symptoms of depression. However, when the symptoms extend for several weeks or even months, it is vital to seek support.

People who experience postpartum depression report experiencing anxiety, guilt, suicidal thoughts, and diminished interest in usually enjoyable activities. Mothers additionally report difficulties sleeping, bonding with, or caring for their child. These symptoms can have an adverse impact on the infant and create a feedback loop of depressed mood and guilt that can prove harmful to both mother and child — but also the rest of the family.

What causes Postpartum Depression?

To fully understand postpartum depression, one might look at how communities and cultures have long approached the period after childbirth. Support, nurturing, and care do not begin and end with the newborn infant but extend to the mother and family. Proper support systems may help prevent postpartum depression.

When there is an insufficient opportunity to recover physically and emotionally or to find a new sense of balance, it may perpetuate pre-existing mental health conditions or catalyze new ones. One of the most significant risk factors for postpartum depression is chronic prepregnancy stress — but anxiety and depression during the actual pregnancy are just as common. The cultural lack of awareness of and support for people throughout pregnancy and the childbirth process likely increases the risk of postpartum depression, so too may any internalized shame or stigma surrounding the birth.

There is also some evidence to suggest that the birth process itself can impact postpartum depression. For example, a 2017 meta-analysis found people who undergo cesarean sections may be at greater risk for postpartum depression. According to psychedelic researcher and father of transpersonal psychology, Stan Grof, cesarean births could have a unique impact on birth trauma. Not only for the mother but also the child whose birth process is interrupted, possibly in a moment of emergency or crisis. (See Psychedelics and Pregnancy.)

Current treatments for PD

Though there are often several unique factors that may contribute to postpartum depression in mothers, the mainstream treatment options are generally limited to those used for treating major depression. Medications such as SSRI antidepressants may be prescribed, as well as other forms of therapy and peer support.

But drug developers are researching alternatives that address the unique needs of postpartum patients. In 2019 Sage Therapeutics introduced the first FDA-approved medication for postpartum called brexanolone. This drug is administered intravenously at an in-patient clinic over the course of 60 hours and is specifically developed to address hormonal imbalances thought to contribute to postpartum depression.

It’s obvious more needs to be done to support maternal health and provide better options for the treatment of postpartum depression. Supplementing one’s diet with herbs and food that support hormonal balance is always recommended to help address symptoms of postpartum depression, but in many cases, pharmaceutical support is helpful.

Research on Ketamine for Prevention of PD

Low doses of ketamine have been used clinically for anesthesia during childbirth for many years to help relieve labor pain. Researchers began experimenting with ketamine to see if using it during cesarean sections would impact the development of postpartum depression. This research has shown mixed results in this context.

A 2017 study found that low doses of ketamine administered during cesarean section did not help prevent postpartum depression. However, a more recent 2020 study countered this finding, suggesting that evidence is inconclusive and warrants further investigation.

Psychedelic Therapy for PD

No clinical trials are investigating psychedelic-assisted therapy for the treatment of postpartum depression — yet. However, compared to daily medications or going to a hospital to receive a 60-hour intravenous hormone infusion, there may be advantages to considering psychedelic therapies.

For example, psychedelic therapies rely on intermittent use of drugs typically spaced weeks to months apart. For nursing mothers, this increases the probability of being able to pump and store enough breast milk in advance that they can undergo treatment with a psychedelic therapy while still avoiding exposing their newborn. Drugs such as SSRIs (e.g. fluoxetine) are known to be transferred to infants in breast milk and can cause behaviors like fussiness or poor feeding.

Psychedelic therapies may represent breakthrough treatments for trauma or PTSD, which may help mothers who feel their depression is related to traumatic circumstances experienced during pregnancy or birth.

Anecdotally, parents are reporting that microdosing psychedelics can help them better relate to their child, and overcome symptoms of postpartum depression. While stories may abound online or in media, we may not know the potential benefits that psychedelics have on treating postpartum depression until research is conducted.

Final thoughts

There is no formal research to date regarding postpartum depression and psychedelic therapies, though there are several reasons to believe it could be of benefit. The use of psychedelics in the postpartum period has special considerations, such as nursing and work requirements. The newborn may also be a factor in conducting psychedelic-assisted therapy, especially if families do not have the support needed. Given psychedelics’ strong track record in helping various mental health conditions by addressing underlying trauma, they are worth researching further for mothers experiencing postpartum depression.

 
Last edited:
chronic-pain.jpg



Psychedelics and women’s health

by Barb Bauer | PSR | Aug 21 2019

More and more women are self-treating with psychedelics to relieve their symptoms.

The bourgeoning interest surrounding the therapeutic use of psychedelic drugs is still a new field of exploration. It’s an ideal time for discussing the unique health and mental health needs of women and how psychedelics may be able to help. Sharp students of the finer points of psychedelic research may ask if the entourage effect is different in women than in men. Keeping this focus will help prevent women from being neglected in psychedelic research.

Historically, the unique needs (and physiology) of women have been underrepresented, ignored, or purposely excluded from drug development and clinical trials. Also, few female scientists have been involved in drug research, including psychedelic research. Fortunately, it’s not too late to shift this paradigm as psychedelic research steams ahead.

Matthew Johnson, associate professor of psychiatry and behavioral sciences at Johns Hopkins says of his psychedelic research.

"We are seeing a demographic shift, particularly among women. We’ve had more females in our studies."

The health needs of women

The mental health needs and everyday challenges of women are many, unique, and the statistics are somewhat frightening.

According to the American Psychiatric Association, every year, one in five women in the US has a mental health problem such as depression, PTSD, or an eating disorder. Depression is the most common mental health issue for women, and twice as many women experience depression in their lifetime than men. Also, women are twice as likely to experience anxiety and PTSD than men. Of people suffering from anorexia or bulimia, 85%-95% are women and women account for 65% of those with binge eating disorders.

The World Health Organization (WHO) says these statistics hold true for women worldwide. Depression, anxiety, psychological stress, domestic and sexual violence, and escalating rates of substance abuse are affecting women more than men on a global basis. The WHO estimates that 80% of the 50 million people around the world affected by civil wars, violent conflicts, disasters, and displacement are women and children. At least one in five women worldwide will be the victim of rape or attempted rape in their lifetime, leading to a variety of mental conditions, including PTSD, depression, and anxiety.

And it’s not just women’s mental health. Women’s overall health also includes pregnancy, breastfeeding, menstruation, post-partum depression, perimenopause, menopause, and coping with miscarriage, stillbirth, and the death of a child, to name a few. This article is not suggesting that women should use psychedelics during pregnancy and breastfeeding, although women are curious and asking questions about it. The point is that ideally, it may be beneficial to treat the overall health needs of women as a separate entity in psychedelic research and give it equal (if not a higher) priority.

Psychedelic mushrooms and women’s health

A July 2019 article in Marie Claire called attention to the growing trend of women self-treating their mental health issues by microdosing psilocybin mushrooms. They microdose to treat their PTSD, depression, anxiety, and ADHD, among other conditions. The women say traditional pharmaceuticals did not work for them or made it feel like they were just walling off the issue, and still not feeling better. Microdosing magic mushrooms made the women feel they could face and deal with the issues that were causing their symptoms. The women weren’t cured, but as a microdosing photographer put it,

"When I do have bad days, I’m able to separate myself from a feeling of worthlessness and stop telling myself the story that I shouldn’t try to connect, shouldn’t be curious, shouldn’t create. Microdosing helps me recognize that I’m still whole."

Another woman said,

"I processed my emotions and let them go in a few hours."

Psilocybin is effective for relieving the symptoms of treatment-resistant depression (TRD) and is currently in phase 2 clinical trials. Of course, there are women participating in this study, and the data may show some differences in the results between men and women. However, research looking exclusively at women and magic mushrooms or pure psilocybin is lacking.

MDMA and women’s health

MDMA presents an excellent example of why women should be considered separately in psychedelic research. The 2016 US Global Drug Survey found that female British clubbers were 2-3 times more likely to seek emergency treatment than men after using MDMA (ecstasy). There was also a 4-fold increase in the last three years in emergency room visits for women who had used MDMA. Researchers theorize that the cause may be related to women’s unique body chemistry. A 2001 study found the psychoactive effects of MDMA in women were more intense than those of men, possibly due to women being more susceptible to the serotonin-releasing effects of MDMA. The effects reported included perceptual changes, thought disturbances, and the fear of loss of body control. The dose of MDMA was positively correlated with the intensity of the effects. Women also had more adverse effects and outcomes from MDMA than men.

The future of psychedelics for women

There is an unmet need for research to discover and understand the unique effects of psychedelic compounds in women and to create formulations with precise amounts of specific ingredients. The research going on now is groundbreaking and critical for the overall understanding of psychedelic therapy. But, consider these questions when it comes to women’s health and psychedelics. Are there are formulations with certain combinations of magic mushroom compounds that would be more effective for treating depression, anxiety, and PTSD in women? Is microdosing different for women? How? Are specific set, settings, and music more effective for women undergoing psychedelic therapy?

The growing popularity of women self-treating with psychedelics and finding relief is a trend that should not be ignored. At the same time, the uniqueness of female physiology calls for specialized research to provide the best possible therapies.

*From the article here :
 
Last edited:
Santo-Daime-Women.jpg



Ayahuasca and childbirth in the Santo Daime tradition*

by Glauber Loures de Assis, Ph.D | Chacruna | 9 Mar 2022

In this article, we discuss the art of midwifery, the relationships of care and support established among women in the Brazilian religion of Santo Daime, and the connection of these practices to sacred plants.

Founded in the 1930s, Santo Daime is the oldest of the Brazilian ayahuasca religions. Founded by Mestre (Master) Raimundo Irineu Serra, a Black man from northeastern Brazil who migrated to the Amazon to work in the rubber industry that developed there in the 20th century, this religion has a female entity, the Queen of the Forest, a “Universal Goddess,” as its spiritual patron.

Some of the most important leaders of the religion are women, including Madrinha (Godmother) Rita, matriarch of Church of the Eclectic Cult of the Universal Fluent Light (ICEFLU), and Madrinha Peregrina, Mestre Irineu’s widow and undisputed leader of the Universal Christian Light Center of Illumination (CICLU) in Alto Santo, Acre (Rodrigues and Assis, 2022).

An aspect still little discussed in the literature on Santo Daime, however, is the female agency within its practices, and the network of support and sisterhood that women have nurtured and kept alive over the decades, despite the difficulties inflicted by a sexist society and the work overload born by many women in Santo Daime.

This network of solidarity can be seen in an especially heroic way with regard to pregnancy and childbirth. There is an art of midwifery, practiced in the Daime tradition, that remains alive, passed on from generation to generation, and protected by zealous guardians.

It is also important to say that this article deals specifically with Santo Daime. Each ayahuasca tradition has its own culture, and what happens in the Daime context cannot be generalized to the whole ayahuasca field.

In Santo Daime, women have the right to drink ayahuasca throughout their pregnancy and during labor. It is a woman’s individual choice, and no one can force her to do so. As in the case of children, pregnant women consume smaller doses (which is often symbolic) than the rest of the group. Pregnant women can also participate normally in the rituals, but are not obligated to do so because they have the freedom to choose.

State and moral entrepreneurs, vocal in sensationalist media, have challenged this freedom over the decades despite the absence of scientific evidence that the consumption of ayahuasca harms pregnant women, fetuses and small children, and families in Daime communities is widely documented in the anthropological literature.

An historic event took place in 2010 when the Brazilian government agency responsible for national drug policy, CONAD, made the decision to guarantee pregnant women the autonomy and right to consume ayahuasca in their religious practices.

This decision remains in effect in Brazil and is a landmark in the country’s drug policy and an example to the world. In the Brazilian context, it is understood that it is up to the woman to decide whether or not to ingest ayahuasca during her pregnancy, and the family has the power to decide on giving the drink to children.

In this case, therefore, the experiences of families over generations and the principle of religious freedom have taken precedence over social prejudice, infamous “war on drugs” policies, and the patriarchal surveillance of women’s bodies.

The use of ayahuasca by women during pregnancy and during childbirth can be seen as an act of resistance to colonial and patriarchal violence, as well as a maintenance of traditional care practices and possibilities to cultivate and share wisdom, knowledge, and experiences linked to the world of midwifery.

Traditional midwives

“It is useless for a woman to say that she is a midwife if there is no trust in the community,” says Clarice Andreozzi, a recognized midwife of the ICEFLU Santo Daime community.

The art of midwifery is involved in the transmission of knowledge between women, and is not a solo, individual activity, but part of a network of support and solidarity with ancient roots.

“It is traditional, ancestral knowledge, passed on from generation to generation,” recalls Clarice, who adds: “The knowledge of traditional midwives is not only linked to labor itself; often it is also associated with knowledge of herbs. Many midwives are prayer leaders and faith healers, and serve as a point of reference in terms of recognizing women in a community. A midwife is a woman that other women trust. She not only takes care of childbirth, but also of women’s problems.”

One of the main historical midwives in the Daime tradition was Madrinha Cristina Raulino. “From the ninth month onwards, Madrinha Cristina started to accompany the women. From the ninth month, a dessert spoon (of ayahuasca) every night. It helps to relax and relieve pain during childbirth,” recalls Vera Fróes, a leading researcher of plants and the female experience in Santo Daime.

Madrinha Cristina mentored and supported many women in the art of midwifery, among them Clarice, who says that she became a midwife to “support women so they don’t go through the same difficulties I did. All the obstetric violence. A total lack of information, in the postpartum period, when I was breastfeeding.”

Today, Clarice is part of the “Daime a Luz” (“Daime-that-births-Light”) Network, a project of women linked to ICEFLU, that seeks to strengthen and empower midwives who live in Daime communities in the forest, “and who become teachers of new midwives,” especially in the Céu do Mapiá headquarters of the Santo Daime expansionist line in Amazonia, founded by Padrinho (Godfather) Sebastião (who is himself a recognized midwife by the community).

The art of midwifery

With the expansion of Santo Daime into large urban centers, the makeup of the Daime community has begun to change, and the new socioeconomic profile of its members is more accustomed to the medicalization of the birth experience, distant from the Amazonian cultural roots of the religion. As a result, the delivery performed by traditional midwives with the use of ayahuasca, even in forest communities, has in many cases been passed over in favor of so-called “modern” methods, and in this way the home/community has given way more and more to the hospital as a place to give birth.

According to Meyer and Meyer (2013), this transition is also related to the average Brazilian’s perception that childbirth is an “illness” or “disease,” which would help to explain the high rate of deliveries performed by modern medicalized means. On the other hand, they point out that the continuance of traditional home births in remote and isolated forest communities is related to the scarcity of resources and difficulties in accessing hospital services.

It is not a question, here, of necessarily placing modern biomedical knowledge in opposition to traditional knowledge. It can be safely said that most followers of Santo Daime do not see a contradiction but rather a complementarity between modern and traditional care techniques.

What interests us here is not a fallacious opposition between “tradition” and “modernity” but rather an opposition between violence and women’s agency over their own lives, bodies, and desires. Here quality information about the possibilities of choice involving pregnancy and childbirth, as well as an appreciation of female expertise in women’s care, play an important role.

It is in this sense that Vera Fróes states that “keeping alive the tradition of humanized childbirth is an act of resistance against the monopoly of health practices and the industrial production of medicines, in addition to valuing our cultural heritage, contained in traditional, intuitive, or empirical knowledge and practices in the use of plants.”


Street art image of Virgin Mary drawn with chalk.



Ayahuasca and the Daime childbirth ritual

We can define living together in a Santo Daime community as a ritualized life experience. There are rituals for all sorts of initiations, from marriage to baptism, and childbirth is no different.

Clarice defines the Daime ritual of childbirth as a “ritual of simplicity, which unites the simplicity of the Daime and the naturalness and simplicity of giving birth.” Women’s faith and trust in their own process are fundamental elements of this moment:

“First of all, with all those who are present, the spiritual works are opened: the Sign of the Cross is made, and the Lord’s Prayer and a Hail Mary are recited. Afterwards, prayers are made, asking Our Lady of Good Birth, Mestre Irineu, Padrinho Sebastião, and our spiritual guides for protection. Soon after we consecrate the Daime [ayahuasca]. Depending on the situation, we may chant other prayers or carry out a hymnal session [a ritual session with singing] until labor starts.

The delivery time varies a lot. That is why we observe the rhythm, the confidence, the presence, the empowerment of women in their process. After a while, we serve a little more Daime, and we can also carry out a smoking or smudging process and provide sitting baths.

When the woman is afraid, we make our prayers and incantations. And we take our spiritual strength to carry out the work. Sometimes the woman wants to meditate. Sometimes she wants to stay in the bathtub. She has the freedom to experience her own process. When the baby is born, we sing the hymn “Sol, Lua, Estrela” [Sun, Moon, and Star], by Mestre Irineu, and the hymn
Sou Luz, Dou Luz [I’m Light, I Give Light] by Padrinho Sebastião. After the baby is welcomed, we say the Lord’s Prayer and a Hail Mary, thank the guides and ancestors who are present, and then we close the spiritual work.

If the placenta takes a long time to come out, there is the prayer of the placenta, for Saint Margarida. In the meantime, we make massages—there are several different techniques, such as steaming the uterus, smoking it with Santa Maria
(Cannabis sativa), invoking her sacred presence—and in this way we carry out the needs that arise during childbirth. Each birth is a new experience, a new learning experience.”

Doctor Adelise Noal, another important Daime midwife, shares some of the emotion of experiencing childbirth within Santo Daime: “The whole body trembles when receiving a newborn human being from the maternal womb, as if it were in a state of trance. The blooming of a flower, watered with the wine of souls [ayahuasca]!"

As can be seen, the Daime childbirth ritual is deeply related to the faith and values shared by the women who make up this religion, a feeling that is shared by the first author of this article, who drank ayahuasca in a Santo Daime church throughout her pregnancies, and considers that Daime also played an important role in the birth and postpartum processes:

“During the entire period of labor to give birth to my second child I took small doses of Santo Daime, which gave me the necessary confidence in myself, in the baby, in the team that helped us, and in the whole process. Although this birth took place in a hospital environment, we were able to set up a small altar in the room. During the baby’s expulsive period, which began to take longer than expected, I drank some Daime, said some prayers, and lit a candle, and from that moment on, the baby was born quickly. On the same day, we moistened the child’s mouth with cotton wool containing Santo Daime, and all this contributed to a meaningful experience, which continued during the puerperium and breastfeeding period.”

Therefore, linking the experience of childbirth to the consumption of ayahuasca within Santo Daime can give participants confidence and support them through the birthing process. This is illustrated by a statement from Padrinho Sebastião, quoted by Vera Fróes, according to which “a woman who drinks Daime does not die in childbirth."
“LINKING THE EXPERIENCE OF CHILDBIRTH TO THE CONSUMPTION OF AYAHUASCA WITHIN SANTO DAIME CAN GIVE PARTICIPANTS CONFIDENCE AND SUPPORT THEM THROUGH THE BIRTHING PROCESS.”

Throughout the history of Western civilization, women have lived with all kinds of violence and interference. Female agency has been constantly relegated to the background, in favor of moral and technical discourses made mainly by men. Despite this, women have been resisting, and the example of the art of childbirth in the Santo Daime religion shows the power and luminosity of women united together.

This power has profound subjective and collective implications, which help to keep the social fabric of the community, its rites, and its culture alive and strengthened in the midst of the various attacks against traditional knowledge, lifestyles, and female autonomy.

We hope that this paradigmatic Brazilian case can inspire people to question the war on drugs, awaken an anthropological sensitivity to observe human cultures in their own terms and worldviews, and fight for women’s rights.

And we also hope that more and more women raise their voices and become protagonists of their own lives, with full freedom over their bodies, their desires, their consciences, and their spirituality. It may be possible for humanity to gestate and give birth to the long-awaited utopia of a better world for all.

*From the article (including references) here :
 
Last edited:
Psychedelics_Heal_Sexual_Trauma_Psychedelic_Spotlight.jpg



Using psychedelics to heal from sexual trauma

by Sophie Saint Thomas | DoubleBlind | 29 Jan 2020

Psychedelics are promising tools to help survivors reprocess their experience and heal from PTSD.

Psychiatrists diagnosed me with so many different conditions after I was sexually assaulted that I don’t remember them all. What was wrong with me? Suggestions included generalized anxiety disorder, insomnia, ADD, panic disorder, and depression. It turned out that I had PTSD, which is an insidious monster with many arms that do indeed manifest as everything from insomnia to flashbacks to depression. What I really wish is that someone had told me: “You were raped, and that is awful, and life is going to be a bit harder now, but you are strong and will be okay.”

While I took SSRIs and went to therapy, my first memory of real healing was through cannabis. It took away nasty flashbacks getting in the way of my sex life. But while cannabis currently may be the most mainstream medicine in the psychedelic community, it’s far from the only one helping sexual assault survivors heal from trauma.

I think that psychedelics can be used as tools to help people access greater embodiment and safety around reprocessing their trauma and, in the words of sex therapist and psychedelic integration therapist Dee Dee Goldpaugh, experiencing a ‘compassionate recasting’ of ourselves in the story,” says activist Leia Friedman, host of The Psychedologist: Consciousness Positive Radio. “MDMA is probably the most commonly used medicine for treating sexual trauma, but I have heard from different people that ayahuasca, psilocybin, ketamine, LSD, and mescaline-containing cacti were all helpful, as well.”

Years after my assault, when that asshole, depression—a side effect of PTSD—showed up again, I began Ketamine intravenous therapy, which has been shown to help both PTSD and treatment-resistant depression. It worked better than anything I had ever tried.

For those like Alexandra Evers, 30, psilocybin intervened. The Detroit-based graphic designer had been in an emotionally, physically, sexually and financially abusive relationship for six years. Against her abuser’s wishes and behind his back, she took shrooms with her best friend. “It was a transformative experience for me, and I believe I would be dead today if I hadn’t gone through with it,” Evers says of that first trip. “I was able to step outside of myself. I saw my life from a wholly different point of view that my inhibitions and denial hadn’t allowed me to see.” Later, alone in her apartment, a realization hit Evers: “I was suddenly overcome with the knowledge that he would kill me. It was a shining moment of perfect clarity that I had never experienced before and haven’t since. I knew that he would murder me if I didn’t pack up and leave. So I left.”

Evers’ experience demonstrates the unique power of psychedelics to provide a lightning bolt of realization. “Psychedelics like mushrooms help you access a shift in self-consciousness,” says Michelle Janikian, author of Your Psilocybin Mushroom Companion: An Informative, Easy-to-Use Guide to Understanding Magic Mushrooms. Evers survived the abusive relationship she was in, but her departure from it was not uneventful. “Two months later my abuser shot himself in the head with a shotgun in that apartment,” she says. “I know that if I had been there, he would have killed me too. I am absolutely sure of it.” Today, Evers continues to use psilocybin on her own with people she trusts to guide her through working on her trauma.

Perhaps a reaction to such a cruel violation, perhaps because survivors who come forward are often called liars, but it’s beyond normal to blame yourself after sexual assault or abuse. Psychedelics, however, may be uniquely poised to treat PTSD stemming from sexual abuse because they help the survivor step outside their traumatized minds and see themselves compassionately. Ketamine works behind the scenes, restoring structure and anatomy, stimulating the dendritic and synaptic growth that was disrupted through childhood trauma. You experience relief about ten hours after the IV infusion (in my experience, a dissociative high is mostly a pleasant side effect), other medicines treat trauma through the trip itself.

Using the psychedelic psilocybin and the empathogen MDMA can both create psychic spaces within individuals to gain a deeper sense of self,” says psychologist and sexologist Dr. Denise Renye. “MDMA can help an individual recollect a sexual assault without the PTSD symptoms of freeze, flight or flight. MDMA can also allow for the survivor to have a sense of empathy for their self that went through the assault, thus alleviating some of the self-judgement that sometimes accompanies it.”

Research shows that PTSD causes changes in the hippocampus, amygdala, and medial prefrontal cortex, which leads to alterations in memory. Psychedelics can help survivors see their experience the same way we’d view an assault that happened to our best friend—with compassion rather than self-blame.

Of course, there is one glaring, deplorable elephant in the room: Most psychedelics are illegal. While this doesn’t prevent survivors from obtaining them, it does make it tricky to do so in conjunction with therapy. “Integration is greatly important. This can be done with a therapist who understands the healing potential of plant medicines and empathogens,” Renye says.

Integration, as the name suggests, refers to integrating wisdom learned from a psychedelic experience into your day-to-day life. It’s wonderful to feel deeply compassionate to yourself during a trip, but speaking therapeutically, it doesn’t matter much if that feeling isn’t harnessed, nor those lessons maintained. “If proper integration is not done mindfully, it will just be a trip and the journey aspect of it will be lost,” Renye says. “It is a journey from feeling broken to experiencing one’s self as whole.” Proper integration, she adds, can be done with a therapist one-on-one, or in a group setting.

Integration is an ongoing process that may include meditation, conscious body movement, mindful walking in nature, and sound healing, Renye says. She also recommends keeping a journal after the journey, as it might be easy to forget the transformations that occurred.

Cities such as Oakland and Denver are decriminalizing psilocybin, and researchers are conducting trials on MDMA, ketamine, and more for PTSD treatment. The future looks hopeful but we—survivors of sexual assault—have a long road ahead of us. For now, if you’re a survivor considering psychedelics, remember how important setting and integration are. “I do not advise recreational use for the purposes of healing a sexual trauma,” Renye says. “I also do not advise doing this sort of experience without the guidance of someone who is trusted and trained. If set and setting are not taken into consideration, there is potential for a deeper level of trauma to occur.”

At the very least, it’s a good idea to have a trusted friend with you to act as a “sitter.” “Before the journey, talk with the sitter about ways to ask for support, such as physical contact like a hand to hold or a shoulder to lean on,” says Leia Friedman. “It’s important to also discuss how to stop physical contact both verbally and nonverbally, and both people must agree that there will be no sexual contact during the session.” Some professionals warn against using psychedelics for trauma without the aid of a trained therapist, because there is a risk of opening old wounds.

I can’t emphasize enough the relief I felt after I found ketamine. It was as if I had been swimming in choppy waters (and acting like it) and suddenly I could stand calmly on land. “How the hell, did I not know this option existed earlier?” I thought over and over. I continued to see a therapist and take my SSRIs, but psychedelic medicine provided a massive change. If you’re a survivor reading this story, until you find your medicine, let me remind you: It’s not your fault.

 
Last edited:
Carrie-Forrest-headshot-small.jpg

Carrie Forrest, MBA, MPH

Homemade CBD Sleep Gummies!

by Carrie Forrest | Sep 18 2018

These Homemade CBD Gummies for sleep are so delicious and easy to make. They can naturally help to improve the quality of your sleep.

CBD has been studied extensively. In regards to sleep, there was an interesting literature review published about the possible benefits of CBD in the treatment of insomnia.

Trying CBD oil for yourself is one of my top eight ways to sleep better.

Homemade-CBD-Sleep-Gummies-4.jpg


There are a lot of CBD gummies and edibles on the market. Since I’m so picky about the quality of ingredients I use, I decided to try making my own CBD Gummy for sleep.

It’s super easy and kinda fun, so that’s why I’m sharing the recipe with you. Also, it’s more affordable to make your own!

Tart cherry juice

Tart Cherry Juice is an amazing supplement. Tart cherries have been studied for their benefits on sleep quality, especially in people who are already having a hard time with sleep.

Tart cherry juice is not only health-promoting, but it tastes great! It is tart, yes, but you’ll see that I off-set some of the tartness with raw honey in my CBD Sleep Gummy recipe below.

The CBD oil I recommend

There are a few reasons I recommend the CBD from Medterra. First, it's 100% free of THC. This means that you won’t fail a drug test and you likely won’t feel any negative side effects.

Homemade-CBD-Sleep-Gummy-1.jpg


Items needed to make homemade CBD gummies

As mentioned, it’s actually really easy to make homemade CBD gummies. You’ll need a few key ingredients, including:

- CBD Oil (I used the 3,000mg tincture from Medterra; it contains 100mg of CBD per 1ml serving)
- Grass-fed collagen gelatin
- Tart cherry juice concentrate (or your choice of juice)
- Raw honey, or your choice of sweetener
- Gummy molds, I used this BPA-free silicone heart mold and this flower-shaped silicone mold

Steps to making your own homemade CBD gummies

- To make the gummies, you’ll heat the juice in a saucepan just to a very light simmer
- Next, whisk in the gelatin and the honey, stirring for about a minute until the ingredients are combined
- Turn off the heat and add two milliliters of CBD oil. Give the mixture one final whisk
- The last step is to pour the mixture into your mold. You can do this without spilling by transferring the mixture into a small pitcher
- Divide the juice mixture evenly into your mold. Place the mold on a baking sheet and set it in the freezer or the refrigerator to set
- Wait at least 30 minutes to one hour before removing the gummies from the molds
- Store the gummies in the fridge for up to 10 days

Get more recipe ideas using CBD in my free e-book!

How long do CBD gummies take to kick in?

Allow at least 30 minutes for CBD gummies to help with sleep.

How many CBD gummies should I take?

Again, it’s a very individual decision to determine how many gummies you should take. I would recommend starting with the lowest dose and moving up from there.

 
Last edited:
ella-byworth-mushrooms-for-anxiety-36cb.png



Meet the women tackling lockdown anxiety with microdosing

by Laura Martin | Metro.co.uk | 7 Jul 2020

'It’s been a total godsend to me during this time, I actually don’t think I could have coped without it,' says Marina. Lockdown has seen many of us turn to crutches – alcohol, cigarettes or junk food – but for this 31-year-old event manager from Walthamstow, it’s been mushrooms. The psychedelic kind.

Every three days, Marina puts one pipette drop from a small brown bottle of mushroom tincture – that she bought for £200 from ‘a friend of a friend’ – on to her tongue.

‘It’s not like taking a big trip,’ she says. ‘Like, I’ve taken LSD at festivals before, and it’s not as intense as that, but I’ve found that it’s helped to calm down the chatter in my head.'

‘I think it’s definitely given me moments of calm when it’s all got a bit too much, and when I’ve needed to work, it’s actually given me a bit more focus.'

‘It never really crossed my mind to try microdosing before, but then this isn’t exactly how I’d pictured 2020 going down.’


Marina isn’t the only one experimenting with psychedelics in lockdown. Behind closed doors in our three-months-and-counting pandemic quarantine, there’s been a resurgence of people who have been experimenting with the fungi. Despite the ubiquitous silver-bullet canisters of laughing gas found all over streets and parks across the UK, it’s magic mushrooms that appear to have become the drug of choice.

While some people – including Marina – have been inspired by American psychologist James Fadiman’s 2011 book, The Psychedelic Explorer’s Guide, which explains the process of microdosing (taking miniscule amounts of a drug every few days to enhance cognitive function), other people are using the drug more recreationally.

‘There’s been loads of times, especially around the beginning of the lockdown, where I felt like I just wanted to take something that would lift me out of it all,’ Corinna, 28, says. She has been taking powdered mushrooms mixed with chocolate when she meets up with friends in Battersea Park.

‘My anxiety has been through the roof recently, I had been using CBD products, but it felt like they weren’t really doing anything for me anymore. The shrooms have been great – everything gets a bit wavy and it’s the only time I can remember laughing in months. It feels like such a release, just for a few hours.’

Mushrooms – at least those containing the psychoactive substance, psilocybin – have been illegal in the UK since 2005, but have been prevalent in civilisations for thousands of years. Ingesting them can cause giddiness, euphoria and hallucinations, and were used by the indigeneous people of Mesoamerica to rituals of the Aztecs, who called it ‘the divine mushroom.’ In 1958, Swiss scientist Albert Hoffman discovered that it was the psilocybin that made these mushrooms so magic. Similarly to when he first took the acid LSD, he noted ‘in a dreamlike state, with eyes closed, I perceived an uninterrupted stream of fantastic pictures, extraordinary shapes with intense, kaleidoscopic play of colours’. He was transported to another place; what we’ve all dreamed of while under Corona quarantine.

In the ‘60s, these psychedelic drugs became central to the US counterculture and as part of the ‘turn on, tune in, drop out’ hippie generation. It was in fledgling studies at this time that first began to link psychedelic drugs’ beneficial effect on people suffering from anxiety, PTSD, depression, addiction, and other mental health issues.

However, in 1971, President Nixon declared his war on drugs, leading all acid and psilocybin-based products to also be banned and classified as Class As, alongside heroin and crack cocaine, as being dangerously harmful and of no medical benefit. The UK followed suit in the same year.

50 years on, the science and health industries have picked up again on this important research. This includes studies on psychedelics at London’s Imperial College and in 2006, a report from Baltimore’s Johns Hopkins research centre found that taking a fraction of a regular dose of psilocybin can lead to feelings of ‘substantial personal meaning and spiritual significance.’

Since then, Silicone Valley leaders have become switched on to the idea of psychedelics and microdosing for ‘optimising their health, and even Gwyneth Paltrow’s The Goop Lab series included a trip to a mushroom therapy retreat in Jamaica.

People are confidently dabbling in these mind-altering substances once again – 15% of 2019’s Global Drug Survey said they had taken mushrooms in the last 12 months, a figure that experts think looks set to rise dramatically as people begin to process this year’s traumatic world events.

‘It’s not surprising to me that people are turning to mushrooms during the pandemic,’ says David Badcock from Drug Science, the leading independent scientific body on drugs in the UK. ‘One reason is that people are locked indoors with nothing to do and want something to amuse themselves, so they might be taking them recreationally.'

‘Also, the increased anxiety related to the pandemic and the uncertainty of everything in the future also means that many people might be using psychedelics to relieve their symptoms.'


How-my-family-LSD-trip-brought-us-closer-than-ever-before-519e.png


‘It’s largely anecdotal evidence at the moment, as there hasn’t been a huge amount of research done yet, but it shows that microdosing has a positive impact on people’s anxiety, stress levels and general mental health wellbeing. Even if it’s a placebo, if it’s having a positive effect, you could argue it’s working.’

At the beginning of the UK’s lockdown, the ONS found that 50% of those polled were experiencing high levels of anxiety. Another study showed that 80% of people working from home felt that the quarantine had caused a negative impact on their mental health. As face-to-face therapy sessions turned to online chats instead, the relentless news cycle became emotionally exhausting. People felt increasingly isolated and began to explore alternatives to their usual self-care methods.

Jess, 33, says: ‘I live on my own and felt myself sliding into a dark place when we weren’t allowed to see anybody else. I couldn’t work out if my weekly Zoom chats with my friends were actually making me feel worse afterwards, as it’s just not the same as seeing everyone in person.'

‘My weed dealer started selling mushrooms as well, so I bought some and made them into a herbal tea and had it one night when we were doing an online birthday party for one of my friends.'

‘It’s hard to describe, but I just felt this real rush of empathy for everyone, I felt like I was really connected with them again. I didn’t feel so lonely or empty. Things seemed a bit more optimistic for me again.’


Hattie Wells, director of Breaking Convention, a biennial global conference on the research into psychedelic substances, explains how the drugs can work: ‘I believe that psychedelics offer a completely different way of looking at, and trying to treat, mental health conditions.'

‘They seem to have the ability to reset certain entrenched responses and patterns of rumination, while also allowing the patient an insight into how these patterns and negative ways of responding to circumstances became bedded in. Understanding one’s condition allows for greater longer-term healing.’

'Although mushrooms can sometimes have side effects such as paranoia or flashbacks for some people,'
Badcock says: ‘Psychedelics are far safer than alcohol. There are many harms associated with alcohol use, from a health, societal and dependence point of view. You don’t take psychedelics then go out and have a fight and end up in A&E.’

Badcock, Drug Science and others are calling for mushrooms and other psychedelics to be declassified and decriminalised to allow for future therapeutic use. However, he adds: ‘You don’t just take the drug and it sorts out all your problems, it needs to be part of a therapeutic package. We don’t advocate doing mushrooms recreationally, but advise it as part of a therapeutic session with psychosocial support. Once the scientific evidence is confirmed, we would love to see the NHS use it as part of the way they treat certain health issues.’

Wells believes that with more trials underway, ‘we’re not more than five years away from away from licensed psilocybin therapy in the UK.’ She adds: “Magic mushrooms are being decriminalised in a couple of American cities, which is how cannabis decriminalisation started over there. However, the UK has been dragging their heels severely. It will be slow, unfortunately, but change is coming.’

Marina can’t wait that long, and says she plans to continue with the microdosing, even after lockdown ends: ‘I’m worried my anxieties might flare up again, but since taking them, I’ve noticed a really positive effect on my mood and outlook. Why would I stop when I’ve found something that works for my own health?

‘It doesn’t really bother me that they’re illegal. I think everyone’s got bigger concerns than people taking some magic mushrooms at the moment.’


 
Last edited:
cannabis-pregnancy-asd-neuroscienews-public.jpg



Cannabis use in pregnancy linked to a greater risk of autism in children

The Ottawa Hospital | Neuroscience News | 10 Aug 2020

Women who use cannabis during pregnancy are at increased risk of their child being diagnosed with autism.

In the largest study of its kind, Ottawa researchers found that children whose mothers reported using cannabis during pregnancy were at greater risk of autism.

The incidence of autism was 4 per 1000 person-years among children exposed to cannabis in pregnancy, compared to 2.42 among unexposed children. The findings were published in the prestigious medical journal Nature Medicine.

Recreational cannabis is now legal in Canada, but that doesn’t mean it’s safe for people who are pregnant or breastfeeding. Health Canada and the Society of Obstetricians and Gynaecologists of Canada recommend against these populations using cannabis, and health warnings to this effect appear on cannabis packaging.

“Despite these warnings, there is evidence that more people are using cannabis during pregnancy,” said Dr. Mark Walker, Chief of the Department of Obstetrics, Gynecology and Newborn Care at The Ottawa Hospital, professor at the University of Ottawa and senior author on the study. “This is concerning, because we know so little about how cannabis affects pregnant women and their babies. Parents-to-be should inform themselves of the possible risks, and we hope studies like ours can help.”

The research team reviewed data from every birth in Ontario between 2007 and 2012, before recreational cannabis was legalized. Of the half a million women in the study, about 3,000 (0.6 percent) reported using cannabis during pregnancy.

The researchers had previously found that cannabis use in pregnancy was linked to an increased risk of preterm birth, and created an animated video to summarize their findings. In that study, they found that women who used cannabis during pregnancy often used other substances including tobacco, alcohol and opioids.

Considering those findings, in the current study the researchers specifically looked at 2,200 women who reported using only cannabis during pregnancy, and no other substances. They found that babies born to this group still had an increased risk of autism compared to those who did not use cannabis.

The researchers do not know how much cannabis the women were using, how often, at what time during their pregnancy, or how it was consumed. They also note that while they tried to control for other factors that could influence neurological development, their study can still only show association – not cause and effect.

As cannabis becomes more socially acceptable, health-care researchers are mindful that some parents-to-be might think it can be used to treat morning sickness.

“In the past, we haven’t had good data on the effect of cannabis on pregnancies,” said Dr. Daniel Corsi, Epidemiologist at The Ottawa Hospital and BORN Ontario, which is affiliated with the CHEO Research Institute. “This is one of the largest studies on this topic to date. We hope our findings will help women and their health-care providers make informed decisions.”

Women who are thinking about or currently using cannabis during pregnancy should talk to their health-care provider to help make an informed choice about what is best for them and their baby.

 
Last edited:
NitrousPatient_Banner.jpg



Largest study finds nitrous oxide safe for women in labor

by University of Colorado | 29 May 2020

Women in labor who had a prior vaginal birth also had low rates of converting to other pain management techniques such as epidural or opioids.

Researchers at the University of Colorado College of Nursing and the School of Medicine Department of Anesthesiology at the Anschutz Medical Campus found that the use of nitrous oxide (N2O) as a pain relief option for individuals in labor is safe for newborn children and laboring individual, and converting to a different form of pain relief such as an epidural or opioid is influenced by a woman's prior birth history and other factors.

The study, out today in Journal of Midwifery & Women's Health, surveyed 463 women who used nitrous oxide during labor. The study is the largest and first of its kind in the United States to report rates of side effects from N2O use during labor, as well as reasons for women in labor after cesarean to convert to other forms of pain relief. Of the women who began using N2O as an initial pain relief technique, 31% used only N2O throughout labor and 69% transitioned to another pain relief method such as epidural and/or opioids. "Nitrous oxide is a useful, safe option for labor analgesia in the United States. And for some laboring mothers, that's all the pain relief they need. Understanding predictors of conversion from inhaled nitrous oxide to other forms of analgesia may assist providers in their discussions with women about pain relief options during labor," said lead author and Associate Professor with the University of Colorado College of Nursing Priscilla M. Nodine, PhD, CNM.

The reason most often cited (98 percent) for converting from N2O to an alternative therapy was inadequate pain relief. The odds of conversion from N2O increased approximately 3-fold when labor was augmented with oxytocin and when labor was induced. Also, those who had a history of cesarean section and experienced labor post-cesarean had more than a 6-fold increased odds of conversion to neuraxial analgesia or epidural. The odds of conversion to neuraxial analgesia decreased by 63% for individuals who had given birth previously relative to those who were giving birth for the first time.

Approximately 4 million women in the United States give birth each year, and for many, coping with labor is a significant concern. Epidurals and spinal blocks, also known as neuraxial analgesia, are the most frequently used pain management tools in the United States, with the main alternative being systemic opioids, which can be associated with both maternal and fetal adverse effects. Recently reintroduced as a pain relief option during labor in the United States, N2O has a long history of use in many developed nations and is increasingly available in the US. "While there is a fair body of anecdotal evidence of safety and effectiveness for how nitrous oxide affects pain during labor, few systematic analyses of outcomes are available from US-based cohorts," said Nodine.

 
Last edited:
feature-l.png



Prenatal cannabis exposure linked to cognitive deficits, altered behavior

Washington State University | Science Daily | 14 Oct 2020

Regular cannabis exposure in rats during pregnancy may cause their offspring to have long-term cognitive deficiencies, asocial behavior, and anxiety later in adulthood.

That's according to a new study by neuroscientists in Washington State University's Integrative Physiology and Neuroscience unit that provides a rare look at the effects of using cannabis during pregnancy.

"The reality of cannabis research is there's not a lot of it," said Halle Weimar, first author on the paper and graduate student in the neuroscience program. "This research helps get information out to women so they can make an educated decision that is best for them."

Weimar and her colleagues found the offspring of pregnant rats exposed to cannabis vapor were more likely to make regressive errors after they were trained new methods to receive sugar pellets. They were also less social and more anxious when placed in new environments.

Weimar said the research is especially significant as recreational and medicinal cannabis use continues to increase among pregnant women as well as the general population.

The study, recently published in the journal Neuropharmacology, utilized a first-of-its-kind e-cigarette technology to deliver cannabis vapor to pregnant female rats before and throughout their entire gestation period.

"The idea was to use a more clinically relevant model to mirror how humans use cannabis, specifically how pregnant women use cannabis," Weimar said.

Researchers also delivered propylene glycol vegetable glycerol mixture, commonly found in vape juice, to explore its effects in rats. A control group was left in their home cage and not exposed to any vapor.

Vapor was administered twice daily to rats in one-hour sessions during mating and pregnancy.

The research team found significant behavioral changes and cognitive deficits that persisted into adulthood in the offspring of the pregnant rats exposed to cannabis.

Using different levers and a cue light, researchers trained and rewarded rats with sugar pellets for pressing a lever paired with the cue light. The rats were then required to change their strategy during test day and instead ignore the cue, which was used as a measure of cognitive flexibility.

"While rats eventually caught on, those whose mothers were exposed to cannabis were more likely to revert to the old pattern and make regressive errors," Weimar said. "They also took more trials to learn the rules."

Male and female juvenile rats whose mothers were exposed to cannabis also engaged in far fewer play behaviors. The male rats were especially hesitant to engage with other rats in their initial social introductions.

Moreover, adult rats whose mothers were exposed to cannabis exhibited anxiety-like behavior in new environments. When placed in a large, elevated maze with open and closed arms, the rats were more likely to stay in the closed arms of the maze and explore the open, exposed arms less.

"They tend to feel safer in closed arms as opposed to rats that are less anxious and willing to venture into open spaces and take more risks," Weimar said.

She said the finding is significant because it shows cannabis vapor administered to a rat during pregnancy may cause its offspring to have age-dependent effects well into adulthood, noting the observation wasn't noted in rats when they were juveniles.

The researchers noticed changes in the rats' behavior as pups as well.

Weimar said rats whose mothers were exposed to cannabis made more than 100 more ultrasonic vocalizations, or cries for their mother, compared to the control group, days after birth.

"It's pretty noteworthy because this is one of the only tests you can do that looks at emotional reactivity in neonates and they were far more reactive than the other groups," Weimar said.

 
Last edited:
https%3A%2F%2Fcdn.cnn.com%2Fcnnnext%2Fdam%2Fassets%2F201124155130-scotland-period-poverty-protest.jpg



Pads and tampons are now free in Scotland. Could the U.S. ever do the same thing?

by Caroline Kitchener | Washington Post | 25 Nov 2020

It's an issue of dignity.

Scotland on Tuesday became the first country in the world to provide pads and tampons to anyone who needs them. In public bathrooms — at libraries, museums, government buildings, schools and universities — menstrual products will now be treated like toilet paper: always there and always free.

When Inga Dale heard the news, she said, she felt like crying.

“It just feels as if you’re valued as a woman,” said Dale, a 30-year-old writing coach who lives in Edinburgh, Scotland. “You are free to have your period, and it’s not something you should be ashamed of.”

The announcement, widely celebrated in Scotland and around the world, could increase pressure on other countries to reevaluate their period-related policies. The U.S. currently lags far behind Scotland, with dozens of states still implementing a “pink tax” that treats period products as luxury goods, adding an extra fee to every purchase.

But experts say the issue has been gaining momentum in the United States, with some state governments doing more to combat period poverty, providing free products in schools. Scotland’s news has led many to wonder: Would the U.S. ever make pads and tampons free?

“The U.S. is on the complete other end of the spectrum from Scotland. We’re still fighting for pads and tampons not to be considered a luxury,” said Lynette Medley, founder and chief executive of No More Secrets, a sexuality awareness nonprofit that distributes free pads and tampons. “But with the new president,” she said, referring to President-elect Joe Biden, “I think people will be talking about it more and more.”

"Period poverty is often discussed in the United States as a faraway issue, affecting people who menstruate in lower-income and developing countries,"
said Anne Sebert Kuhlmann, a professor of public health at Saint Louis University and board director at Dignity Period, a nonprofit dedicated to increasing access to menstrual products.

"While Dignity Period originally focused only on providing pads and tampons to women in Ethiopia," Kuhlmann said, "their focus quickly expanded to include the many women who can’t afford pads and tampons in their own city."

“We realized there wasn’t much data that showed the magnitude of this problem in the U.S.,”
she said. In her 2019 study of 183 low-income women in St. Louis, Kuhlmann found that 64 percent had to go without period products in the past year.

“It’s an issue of dignity,” she said. She says she'd met women in St. Louis who couldn’t afford pads and tampons and would quickly bleed through their one pair of underwear. “How does that make you feel when you can’t take care of yourself?”

Most efforts in the U.S. so far have focused on schools. Four states — New York, California, Georgia and, most recently, Virginia — now require middle schools and high schools to stock their bathrooms with sanitary products, allowing students to take as many as they need. "These measures are making an impact," said Claire Coder, founder and chief executive of Aunt Flow, which manufactures menstrual products for schools. New York began offering free products across the state after a successful pilot program. With free pads and tampons, attendance rates for girls rose by 2.4 percent.

Scotland also started by providing products for students, requiring all schools and universities to offer free pads and tampons in 2018.

"Free access in schools is one step in the right direction," said Medley, "but it’s important that countries don’t stop there. Period poverty is often a barrier for unemployed or underemployed women trying to break back into the workforce," she said. "If they can’t afford pads and tampons, they might have to miss interviews or days on the job." "School-based measures are particularly inadequate during the pandemic," she said, "when many students are learning from home."

EndQc8oXMAAfHi3.jpg


Many period activists celebrated the Cares Act, passed by Congress in March in response to the coronavirus, for including menstrual products on a list of health expenses eligible for reimbursement for people with a health savings account (HSA) or a flexible spending account (FSA). Medley was more critical: "This legislation addressed the needs of the 'haves' who could afford an HSA or FSA," she said, "but not the “have-nots.”

"If Congress really wanted to tackle period poverty during coronavirus,"
she says, "they would have offered free menstrual products to anyone on Medicaid or Medicare."

Medley blames deep-seated stigma for the government’s lack of action. "It’s hard to hold high-level conversations about product accessibility when periods are widely 'demonized' and treated as 'something dirty,' she said. "Regular people — both men and women — often struggle to talk about menstruation. In my work," she says, "I am constantly urging women not to hide their pads on their way to the bathroom, or wait to buy tampons until there’s a woman at the cash register."

"Women are less likely to sound the alarm on a period-related problem,"
said Kuhlmann.

"It’s important to have female legislators who can personally understand the issue," she said. "Scotland’s top government official is First Minister Nicola Sturgeon. It’s much harder to imagine this happening with a man in charge," Kuhlmann said.

“She has that lived experience,” said Dale. "Women are in a unique position to solve this problem," she said. "Since parliament passed its new menstrual policy on Tuesday, she’s seen quite a few men on Twitter criticizing the legislation, asking why pads and tampons should be free."

“I’m like, excuse me, you don’t get your period, so you don’t get an opinion,”
she said.

"Other countries might follow Scotland’s lead," said Kuhlmann, "and enact sweeping, national reform on menstrual product accessibility. But it’s unlikely to happen in the United States anytime soon, she said. U.S. reforms will probably happen state by state, she said — starting in schools."

"More data will be critical. To convince U.S. legislators that free pads and tampons are necessary, activists need to be able to pinpoint the 'longer-term costs' of people missing work and school because they can’t afford these products,"
Kuhlmann said.

What’s the trade-off there? What’s the economic impact?

"It’s probably much larger than anyone expects," she said.

 
Last edited:
Chacruna's Women and Psychedelics Forum, Parts 1-3







 
Last edited:
honoring-my-inner-goddess1.jpg



One woman's story about how psilocybin helped her quit smoking

The Atlantic | 26 Jun 2016

Kathleen Conneally had smoked since she was 12, but one day in the spring of 2013, that changed. Conneally arrived at a lab in Baltimore that looked more like a cozy living room, with a cream-colored couch and paintings of mountains on the walls. She took a pill from a golden goblet and popped it in her mouth. In the care of trained guides, she began to see wild colors, shapes, and ideas.

Conneally was a participant in an addiction study conducted by researchers at Johns Hopkins University, who wanted to determine whether the relentless pull of nicotine could be weakened by psilocybin.

Conneally’s trip, the second in a series of three such “sessions,” was probably the best outcome the researchers could have hoped for. She saw herself as purple flower rising high above her earthly problems, which looked small and stupid by comparison. Even more measly and insignificant was an image of herself, huddled and puffing on a cigarette.

“Just breathe, and there’s no smoke, and no chemicals, and no problems,” she recalled herself thinking.

Leaving the lab 5 hours later, she was sure she would never smoke again. Before, the stresses of her life would stir an overwhelming desire for cigarettes. But now, she said, “I can just cross that off my list. I don’t have to do it anymore.”

She hasn’t had a cigarette in more than three years.

There were 15 people in Conneally’s study, and 12 of them quit smoking—a much higher success rate than the 35 percent or so who quit through other methods. A much larger study is now underway to verify the results.

Matthew Johnson, an associate professor of psychiatry at Johns Hopkins and the lead author of the study, was interested in psilocybin because of the success researchers had in using LSD to treat alcoholics in the 1960s. He liked that psilocybin was shorter-acting than LSD and had less societal stigma. It also has few side effects or addictive properties of its own.

According to Johnson, depression and addiction both involve a narrowing of vision—a tunnel that it takes a profound experience to suck someone out of. "Psilocybin," he says, "can foster something called cross-talk between regions of the brain that don’t normally communicate. Cross-talk, in turn, is associated with novel ways of looking at problems."

They’re “dealing with stuff they haven’t dealt with in years or decades,” Johnson said. While tripping, “people reflect on their childhood, their parents, their siblings, all their relationships, their love life, their current relationships.” Meanwhile, their minds become a kaleidoscope: “Colors are brighter. The walls might be waving. There might be a halo around things,” he said.

Addiction to cigarettes consists of much more than physical cravings. It’s social. At best, it’s a ritual, and at worst, a crutch. Psychedelics appear to help people go beyond physical cigarette cravings and examine what’s really making them smoke. “People will recognize this profound self-worth that they’ve dismissed,” he said. “They look at their life and see themselves as a miracle.”

Though she began smoking during as a child, Conneally quit cold-turkey when she was 27. But she picked it up again in 2008, when her life was “pretty much falling apart,” as she describes it.

That year, she turned 40, and the economy crashed. Conneally’s partner, Whitney, was laid off. Finances grew tight and difficult to manage, which felt cruelly ironic to Conneally, a certified public accountant.

“Happy 40th birthday,” she thought. She reached, as she always had in pressure-cooker moments, for her cigarettes.

This time, she figured she was never going to quit. She'd tried everything from gum to hypnosis. She white-knuckled through a few cold-turkey attempts and scared herself with how it made her scream at the kids.

But when she heard about Johnson’s study, she thought, “why not?” A Dead-head back in the day, she was no stranger to trippy experiences. At least it would be fun, she thought.

The first session was assuredly not. “I started to panic and have anxiety thinking that I wasn’t doing it right,” she said. She worried the trip wouldn't work, and as a study participant, she wouldn't be allowed to smoke when it was over.

Conneally sunk into a depression after the first trip. A few weeks later, she cried on her way to the second session.

But this time, something was different. The music was better; she felt freer. “My spirit soared,” she said. “I had this great vision of rising above and being a goddess.” She saw her worries like ants in the distance: Her abusive father; the air-conditioning unit where she would hide from her family and smoke. The participants in Johnson’s study had weeks of talk therapy before they tripped. Now everything she had talked about with her counselors was coming together. “I just am,” she thought, “and I need to let go of this stuff.”

A sense of mysticism seems central to the trip treatment. Eleven of Johnson’s 12 study subjects rated the psilocybin trip among the five most spiritually significant experiences in their lives. Some considered it a crash-course in mindfulness, or years of therapy crammed into a single day.

Johnson cautions that his study doesn’t mean people should take mushrooms on their own to cure various ailments, or at all. People don’t necessarily need to take psychedelics to break free of their destructive brain patterns. It can happen with any mystical life experience—the kind that changes everything that comes afterward. Living in a foreign country, giving birth to a child, and even falling in love—all of these approach the brain-rearranging power of psychedelics, at least for some people.

https://www.theatlantic.com/health/a...hrooms/487286/
 
Last edited:
Screen-Shot-2021-03-08-at-12.05.52-PM.png



Women on psychedelic leadership: A roundtable discussion

by Hadas Alterman | LUCID | 6 Mar 2021

All over the country, women are taking the lead in the psychedelic decriminalization movement. Despite differences in background, education, and age, these women share a common thread: they have all found themselves working on initiatives that are predominantly male-led, and have found themselves navigating the gender dynamics of their respective organizations. Of course, none of that is novel. However, despite the usual pressures to ignore their feelings, put their heads down, and follow the (male) leaders, they are utilizing their natural strengths as women (eg: intuition, emotional expression) as assets in furtherance of their work, and seeing positive results.

In January, Lucid News brought together a group of women on Zoom to discuss being bossy, psychedelic policy, SSRIs, and the power of storytelling. The conversation was moderated by Hadas Alterman, a Founding Partner at Plant Medicine Law Group LLP.

Participants:

Charlotte Blocker was the Political Outreach Director of Measure 109, Oregon’s psychedelic-assisted therapy initiative. She is currently serving as the Board Treasurer for the Oregon Womxn’s Campaign School, a non-partisan, volunteer-led nonprofit which trains reproductive champions to run successful political campaigns.

Julie Holland, MD is a psychiatrist specializing in psychopharmacology, with a private practice in New York City. She is the author of several books, including Moody Bitches: The Truth About the Drugs You’re Taking, The Sleep You’re Missing, The Sex You’re Not Having, and What’s Really Making You Crazy; Good Chemistry: The Science of Connection, from Soul to Psychedelics; and ECSTASY: The Complete Guide.

Melissa Lavasani
is the Founder, Chairwoman, and Executive Director of Plant Medicine Coalition. Prior to founding the Plant Medicine Coalition, Melissa was the proposer of Washington DC’s successful 2020 ballot measure Initiative 81, the Entheogenic Plant and Fungus Policy Act.

ON BEING BOSSY

Hadas
: Dr. Holland, in your book, Moody Bitches, you describe a study of women’s performance reviews that shows how words like “bossy” and “abrasive” are consistently used when women are leading. The same studies also shows that when women are objecting to something, we see words like “emotional” and “irrational.” You also note that SSRIs generally reduce aggression, and irritability and promote cooperative behavior.

Julie: As does estrogen, by the way,

Hadas: Right. So, Charlotte and Melissa, I’m curious if this resonates with your experiences working on your respective campaigns. Did you feel like your colleagues would have preferred a more, metaphorically, “SSRI-ed” version of yourselves?

Melissa: I’m sure there were moments when people wanted that. But I, quite frankly, didn’t care. I knew that we had a goal, an extremely difficult goal. Then the pandemic amplified all of the challenges of a regular campaign, which I’m sure Charlotte can relate to. My entire life was out there for the public to evaluate and pick apart. I made it clear on the campaign that I have final say over the decisions being made. Not in a micromanaging way, but we had to carefully package our messaging, and who we are as [an organization], in a specific way. I was very careful about it. Everything was extremely thought out, down to the most minute detail of our materials that [were mailed] to people’s homes. When you’re going into situations like that you are in a leadership position, and you have to have some tough skin. When there are those in the room that object to you, it’s just a friendly reminder that, you know, this is the system that we created, and this is what’s going to get us to that win. So it didn’t really bother me if anyone didn’t like me. I know that’s kind of a weird thing to say. But our colleagues either got it,or they didn’t. And the people that got it understood that we were working for a greater good, and there was a reason why things had to be done in a certain way. I knew going into this I was not only going to have some people not like me on the campaign, but there might be people in the public who think I’m a bad person for taking drugs and exposing my family to drugs. You know, all the scare tactics and paranoia that people have surrounding drugs. I just had to accept that as a part of this entire journey.

Charlotte: Well, I have to say, as a long-time taker of an SSRI, I don’t know if everyone I’ve worked with would agree that it reduces my aggression and promotes my cooperative behavior. One thing that comes to mind is that Vice President Harris had a great quote where she said that there are always going to be people who tell you that you’re out of your lane. They’re burdened by having only the capacity to see what has always been, instead of what can be. But you can’t let that burden you. That’s always been my approach to working on campaigns. Progress is always made by challenging a status quo. You have to challenge that status quo at every level you possibly can to make the best amount of change you can, especially in campaigns that cater to this very patriarchal society. From all the way across the country, I read Melissa’s story and I knew what was going to happen in DC. But I only knew that because Melissa went out there and put her story front and center. And her story isn’t an uncommon one, right? So many families deal with the same issues. As an advocate you have to be willing to put your story out there. You don’t have to be comfortable with it, but you have to recognize that you’re not alone.

Julie: My brain is still stuck on the word “bossy”, which it turns out, I have a lot of shenpa around, because it’s something that I was called so often when I was younger. Do boys ever get called bossy? Why not? What’s up with that? I was a natural born leader. Wouldn’t it have been great if my parents were like, “Wow, you’re a leader”, instead of like, “Hey, tone it down.” And when I was growing up, I didn’t know what “mansplaining” was, but it would have been really good to have that vocabulary. Because I look back now at how many times that happened, where I was being schooled on something I knew everything about, but because I was a woman, it was assumed that I didn’t. Now you could just be like, “please don’t mansplain” but I was in my twenties and there wasn’t a word for it. I just knew that I felt tremendous humiliation and anger. I eventually found my way and embraced that I am bossy. I do like to tell people what to do, and I’m good at it and I can do it in a charming way. I ran the psychiatric emergency room for nine years, two shifts a week. I was in charge. And I got much more comfortable with just being in charge, and if you don’t like it, that’s not my problem. How you feel about me doing my job is not my problem – I’m doing my job. At some point, it became liberating to not be the one that has to carry it. It’s internalized misogyny if I’m carrying it – and again, we did not have that phrase when I was growing up. It took me a long time to figure out that I had internalized a lot of things from my father, who grew up in the Fifties, with the “a woman’s places in the kitchen” kind of thing. I think my mom was secretly nudging me toward leadership roles, and daring to be great.

Hadas: You mentioned the combination of being bossy and charming. Although “charm” has a positive connotation, the opposite of bossy, it’s also simultaneously taboo for a woman to operationalize charm to accomplish things at work.

Julie: If I could make a list of all of all the phrases that were applied to me in my evaluations over the years as a medical student, as a resident, there would be many mentions of this issue of knowing. Knowing what was right and saying what was right, even if it was not politically correct, or appropriate. For instance, there was a woman who just had twin boys. And as she was being sewn up by the gynecologist, the father of the children was like, “Hey, throw a couple stitches in there for me, Doc!” And I was just like, “What the fuck? She just had to two children, like two people come out of her vagina, and you’re worried about the next time you fuck her!” The doctor actually stomped on my foot so I would stop talking. But I was incensed. That’s the most I’ve ever spoken out of turn and I got in a lot of trouble for it; they called me a loose cannon. I would probably say that again, just maybe not swear so much.

ON SSRIs, WOMEN AND PSYCHEDELICS

Hadas
: I have been on and off SSRIs before, and I have, at various points, found them extremely helpful, and then not helpful. The fact is, SSRIs save some people’s lives, and for some people they simply do not work. I find this to be a really touchy subject, and, as an advocate, it can be challenging to navigate it a non-shaming, inclusive way.

Julie: Not only do SSRIs not always work, but there seem to be situations where they make things worse, where somebody is on SSRIs for decades, comes off of them, and can’t be off of them because they were on them for so long. When we looked at everybody who received MDMA from the phase two trials, the people who had been on SSRIs for years did not respond very well to MDMA, didn’t have big physiological changes, and didn’t have great reductions in their PTSD symptoms the way that people who had never been on SSRIs did. Which implies that maybe these SSRIs are going to get in the way, at least with MDMA. And they’re possibly already in the way; I have tons of patients who are on antidepressants who would like to have ayahuasca or psilocybin or microdose, but they’re on these meds, and the meds are interfering. This is something everybody’s going to have to navigate and figure out.

That said, I prescribe SSRIs all the time. The bulk of my patients are taking SSRIs with or without other meds. And they do help you not care so much about how fucked up things are. Maybe that sort of, you know, levels the playing field where you’re acting more like a man who doesn’t necessarily care as much about how their actions are going to be received or perceived.

Hadas: I think it’s going to be a particularly interesting phenomenon for women, because we make up such a disproportionately large percentage of the population that is being prescribed SSRIs consistently.

Melissa: I personally have never been on an SSRI. I was prescribed an antidepressant when I was pregnant with my son, but I didn’t take it. I had a couple of really close friends who had been on antidepressants, SSRIs and others, and just seeing how their lives progressed on the medication, and actually losing a friend that was trying to wean off who took his own life – it scared the shit out of me. That’s when I decided to not get on anything and power my way through my depression, which I failed at miserably. But I acknowledge that on the campaign. The message can’t be that antidepressants are bad, and that traditional therapy is bad. Ultimately, antidepressants have saved people’s lives. We just need to be talking about the fact that it’s not the only option, and ask how can we change the current structure in this country for dealing with mental health? How can we incorporate psychedelics, which, the research is showing, are effective therapies? But it’s a delicate dance, because you’re talking about people with mental health issues and the relief that they’re finding. I saw an article entitled “The War on Antidepressants” and I clicked on the comments, which you should never do, but I did it because I was curious what people were saying about it. It was all these people defending SSRIs and how that medicine saved their lives. We can’t be the movement that’s like, “Well fuck all this shit that’s already here!” We have to speak to everybody. Not that psychedelics are for everybody. But we can’t just alienate large swaths of the population who are getting relief from traditional therapies.

ON STORYTELLING AND DECRIMINALIZATION

Hadas
: Melissa, you set a precedent for these campaigns. Your campaign was narrative-centered, and it was centered around the emotional experience of a woman who had just given birth, and then used plant medicine to heal. There’s so many pieces of that that are taboo. You talked about all of it, and it worked.

Melissa: I knew that for DC, the message would have to be a little different. It was really important that we led with the heart and the soul of this entire experience. Initially, I thought what I would bring to the table was political connections that me and my husband had from working in government in DC. I in no way wanted to be the spokesperson for any of this, because I thought it was way too risky. But when we were planning everything out, I came to the realization that it had to be me. I actually backed out of it the night before we were supposed to submit the paperwork. I said, “I can’t do this. My kids are at school here and the parents are gonna ostracize them, and no one’s gonna speak to us. And then I’ll have to move.” I was doomsday-spiraling out of control the night before. But my husband and I talked for two hours that night. And it was one of those moments. I felt like this was the right thing to do, and that people would understand this, and that I should move forward and give it a try. Thank god it worked.

Hadas: Back in September I was talking to Measure 109 Campaign Director Sam Chapman about how things were going in Oregon and he said something about how soccer moms just loved the campaign, and they were winning over all the moms. And then we have Melissa’s motherhood-centric narrative. Do you think that there’s something about feminine energy that made the general public more comfortable with something that would otherwise scare them?

Julie: For a lot of people, when they hear about drugs, they’re just afraid. It’s fear of the unknown, fear of the unexplainable, the mysterious yin energy. It’s not straightforward the way yang is. But I also think that, because these medicines are so heart opening, people who have a lot of experience with them are willing to be very open hearted, and not so rigid. The yin energy is all about receptivity. The four of us may be more yang than yin when you get down to it. But you know, we still have both. And we can learn to juggle both. I’m very yang and I’m very results oriented and driven, and I have a list and check things off of it. Yang is like having a vector, while yin is about being open and receptive. Reflective, integrating things, figuring out things and reflecting back, and not projecting onto other people. But that is very hard when you’re dealing with something scary. And two yangs coming at each other is just friction and chaos. So you want that blend.

These medicines are so heart opening, and they get us in touch with our yin energy, our receptive energy. When you’re tripping you learn how to be open to things, and then you try to teach other people how to be open to things. The fact that these are neuroplastic medicines that help people rewire their circuitry and refigure things out means that they need to be contained in something like a holding environment. It’s like being a therapist; you create a holding environment, and then the person feels comfortable to change. If you have a therapist who’s like, banging you over the head and being too yang, you just kind of close down. You need somebody to be open and receptive to your fears. It may be that women are inherently more soothing and less threatening than men. People love a good story that they can connect to; obviously Melissa experienced this, and whenever I’m writing about psychedelics for a women’s magazine, or an Op Ed, they always want you to start with a human interest story and a hook. You can’t just say, this is how this medicine works, and this is what’s going on with drug policy. You need a story because that’s how you get the empathy and yin heart-opening experience. There’s this great line: “People resist what they’re told, but they never resist what they conclude.” You just want to give them enough information that they think they came up with it themselves. I honestly think that women are better at laying down the groundwork. Maybe we’re more emotionally manipulative. That’s how we’ve learned to be. But with something so scary and big, and hard to define and deal with, you have to come at it from the edges and not head on.

ON PSYCHEDELICALLY-INFORMED CAMPAIGNS AND TOKENISM

Hadas
: What is a psychedelically informed campaign? What does that look like? How does that operate differently then the garden-variety political organization?

Melissa: It’s important to have different perspectives here. Our campaign worked with the same infrastructure that the cannabis reformers had here, and Dr. Bronner’s played an integral part in the campaign as well. It was a lot of white people, a lot of cisgendered people. It started that way, but as soon as I got a little bit more press, people who were interested in psychedelics but didn’t fit into that mold or were intimidated by a political campaign, reached out to us. Acknowledgement that there’s a woman running this campaign – she’s a mom, she’s a professional. completely different than anything that they’d seen before. And that attracted the others. By the end of it, I was super proud that we had such a diverse coalition of people supporting us. It was a beautiful thing. Did we still deal with misogyny? Yes. But the system’s not going to change overnight.These little movements forward are important and hopefully it’ll change campaigns going forward. It was intentional. I didn’t want this to look like the cannabis movement. It couldn’t look like the cannabis movement. The activists here were sensationalizing cannabis use, which brought a lot of attention to the issue. We were doing the opposite because, quite frankly, psychedelics are already sensationalized and we needed to normalize them. By normalizing them, we attracted a diverse group of people.

Charlotte: For the Measure 109 campaign, one of the most important things we did was create a Healthcare Equity Committee populated almost entirely by BIPOC leaders from around the country and not the typical cisgendered white male, which I think dominates most other committees like this. And it was powerful in multiple ways. Some of these leaders were able to point out practices that have been done for millennia, by individuals from cultures that have used plant medicine for centuries before the white man ever found it and started using it. They were able to talk about that from experience, and from a culturally enlightened perspective about what that meant. There were individuals who sat on this committee who have been in the cannabis space for a long time, and have seen the corporatization of cannabis, how quickly it went from being the people’s plant to a corporate commodity. I think one thing our campaign did well was to create space for those voices, to listen to those experiences in a serious way. Allowing those voices to steer your campaign is very powerful.

Hadas: How much was the Healthcare Equity Committee actually able to steer, as opposed to just being there for optics? And was there resistance to the suggestions raised by the Committee members?

Charlotte: I was on the campaign for 10 days before we went fully remote. At that point, it was myself and our campaign manager as paid staff. That was it. And we literally had to throw the rulebook out the window, and build and rebuild and break down and rebuild this campaign again, and again, and again, because traditional politics, traditional campaigns, as we know them, would not work during Covid. It was a great precursor to creating the Equity Steering Committee, and then actually listening to them. It didn’t really matter what we thought was going to work or what wasn’t gonna work, because we were not able to knock on doors or meet in person. So there was some benefit in totally throwing that rulebook out the window.hen individuals spoke up and said, this is how it is in our culture, and this is why it is, and this is why we think it’s important to continue and go forward in this direction, we were able to actually listen to it because we didn’t have a lot to lose at that point in the campaign.

Julie: I’ve been in the cannabis space for twenty-something years, on different scientific advisory boards, medical advisory boards, etc, and sometimes I would be at a board meeting, and it was just me and a bunch of men. I’m like, I’m your token woman, and I’m just here because I’m a woman, but maybe you can hear what I have to say, anyway. I would jokingly address it head on: I’m here because I have a uterus. But the bottom line is, these guys didn’t realize that half the adult population has cramps every month and you may want to formulate a cannabis product for these customers. They’re not thinking about these things. So when they saw that I was actually bringing a different perspective, I was valued. I have friends who are women of color and they’re complaining because they’re being used as a token. If I want to be on a board and somebody wants me to be on a board, I know it’s because I’m a woman. But I’m going to go ahead and do a really good job so that they keep asking more women to do it. We have to start somewhere.

 
Last edited:



How psychedelics helped me feel safe in my body, in my pleasure, in my vulnerability, and in love.

by Mareesa Stertz | LUCID News | 20 Jan 2021

I now know what it’s like to have found the frequency of safety, and to feel safe in my body, in my pleasure, in my vulnerability, and in love.”

In this episode of Adventures of the Psyche we are joined by Dena Justice, who shares how a series of psychedelic journeys unraveled deep patterns of co-dependency, control, disassociation, and physical unwellness stemming from childhood sexual abuse.

Dena spent most of her life highly anxious, sleep deprived, disassociated from her body, and haunted by memories of childhood abuse – and thought there was nothing wrong. It took five years of psychedelic work, and other healing modalities, to help her unpack her childhood trauma, and feel truly alive.

Dena is the founder of Psychedelic Ministry and Ecstatic Collective. As a master coach and certified trainer, she certifies others in Neuro-Linguistic Programming (NLP), Time Line Therapy®, Hypnotherapy, and NLP Coaching. She integrates these practices into non-ordinary states of consciousness (such as meditation, breathwork, movement, and psychedelics).

Join filmmaker and host Mareesa Stertz for a brief visit into other realms where guests share personal stories of illumination, healing, and transformation through their use of psychedelics.

*From the article here :
 
autoimmunity-offset_721881-1024x780.jpg



Why women are more prone to autoimmune diseases

University of Michigan | Science Daily | 19 Apr 2019

Women are four times more likely than men to have an autoimmune disease. And more than nine times as likely as men to have lupus. The reason for this gender bias has evaded scientists. Researchers have hypothesized that female sex hormones like estrogen may play a role in stimulating the immune system, but others argue that this doesn’t tell the whole story. A new study by researchers at the University of Michigan suggests that part of this story may be told within the skin. Women have previously been shown to have higher levels of a protein called vestigial like family member 3 (VGLL3) in their skin. VGLL3 regulates certain immune-related genes that may play a role in autoimmune diseases.

The Michigan researchers decided to test what would happen if they increased levels of VGLL3 in the skin of mice. Would this cause them to develop autoimmune conditions more easily than control mice with normal VGLL3 levels? After six weeks, mice that had been genetically altered to have higher levels of VGLL3 started to develop thicker skin and scales around their face, a telltale symptom of lupus. They also had significantly higher inflammation and biological markers of early-onset lupus than the control mice. Next, the researchers analyzed skin samples from the mice and compared them to skin samples from humans with lupus. There was considerable similarity in gene expression between the skin of the altered mice and the lupus patients. Identifying VGLL3 as a potential trigger of increased autoimmune diseases among women is the first step—and it’s incredibly exciting. The next step, though, may be a bit more difficult: determining what causes women to have raised levels of VGLL3 and how to stop it from wreaking havoc on the body.

Part of the answer, it turns out, may lie in the skin.

New evidence points to a key role for a molecular switch called VGLL3. Three years ago, a team of University of Michigan researchers showed that women have more VGLL3 in their skin cells than men.

Now, working in mice, they've discovered that having too much VGLL3 in skin cells pushes the immune system into overdrive, leading to a "self-attacking" autoimmune response. Surprisingly, this response extends beyond the skin, attacking internal organs too.

Writing in JCI Insight, the team describes how VGLL3 appears to set off a series of events in skin that trigger the immune system to come running -- even when there's nothing to defend against.

"VGLL3 appears to regulate immune response genes that have been implicated as important to autoimmune diseases that are more common in women, but that don't appear to be regulated by sex hormones," says Johann Gudjonsson, M.D., Ph.D., who led the research team and is a professor of dermatology at the U-M Medical School.

"Now, we have shown that over-expression of VGLL3 in the skin of transgenic mice is by itself sufficient to drive a phenotype that has striking similarities to systemic lupus erythematosus, including skin rash, and kidney injury."

Effects of excess VGLL3

Gudjonsson worked with co-first authors Allison Billi, M.D., Ph.D., and Mehrnaz Gharaee-Kermani, Ph.D., and colleagues from several U-M departments, to trace VGLL3's effects.

They found that extra VGLL3 in skin cells changed expression levels of a number of genes important to the immune system. Expression of many of the same genes is altered in autoimmune diseases like lupus.

The gene expression changes caused by excess VGLL3 wreaked havoc in the mice. Their skin becomes scaly and raw. Immune cells abound, filling the skin and lymph nodes. The mice also produce antibodies against their own tissues, including the same antibodies that can destroy the kidneys of lupus patients.

The researchers don't yet know what causes female skin cells to have more VGLL3 to begin with. It may be that over evolutionary time females have developed stronger immune systems to fight off infections -- but at the cost of increased risk for autoimmune disease if the body mistakes itself for an invader.

The researchers also don't know what triggers might set off extra VGLL3 activity. But they do know that in men with lupus, the same VGLL3 pathway seen in women with lupus is activated.

Many of the current therapies for lupus, like steroids, come with unwanted side effects, from increased infection risk to cancer. Finding the key factors downstream of VGLL3 may identify targets for new, and potentially safer, therapies that could benefit patients of both sexes.

Lupus, which affects 1.5 million Americans, can cause debilitating symptoms, and current broad-based treatment with steroids can make patients far more vulnerable to infections and cancer.

Patients' role in future research

Their colleague and senior coauthor Michelle Kahlenberg, M.D., of the U-M Division of Rheumatology, is now recruiting patients with lupus for a study sponsored by U-M's A. Alfred Taubman Medical Research Institute that could provide answers to these questions and more.

Billi, a resident in dermatology, notes that when she speaks with patients who come to Michigan Medicine's dermatology clinics for treatment of the skin problems lupus can cause, she has to acknowledge the limits of current treatment. Even so, she says, patients are eager to take part in studies by contributing skin and DNA samples that could lead to new discoveries about their condition.

"Many patients are frustrated that they've had to try multiple therapies, and still nothing is working well," she says. "To be able to tell them that we're working on a mouse that has the same disease as them, and that we need their help, brings out their motivation and interest in research. They know that it's a long game, and they're in for it."

*From the articles here :
 
Last edited:
640px-Anais_Nin.png



Anaïs Nin and the vocabulary of the psychedelic experience*

Zoë Dubus, Ph.D.(C) & Pierre Leger | Chacruna | 12 May 2021

Compared to other psychotropic drugs available in the 1950s, LSD induced “something phenomenal, … of unimaginable intensity,” according to its creator Albert Hofmann. Speaking in an interview in 2004, he continued, “There is a vast difference between the emotional experience of this sensation and its purely abstract, philosophical description. It would be like trying to describe colours to a blind person: words alone will never make it possible to see what they are.” How can the psychedelic experience be described when it eludes translation into language?

Authors involved in the early study of LSD had been forced to resort to new concepts to explain what the experience was like. A specific vocabulary had to be invented in order to describe these phenomena. Following a tradition established by the psychiatrist Jacques-Joseph Moreau de Tours (1802–1884) with his work on cannabis, where he used the insights of writers and artists, this process was not just a scientific endeavour: intellectuals such as Aldous Huxley (who helped coin the word “psychedelic” with Humphry Osmond), Anaïs Nin, Ernst Jünger, Gérard Heard, and Henri Michaux all participated in the development of these concepts, thanks to their ties with the scientific community.

For inspiration, researchers, artists, and writers turned to Eastern philosophy—with its heightened attention to the body, in contrast to the Judeo-Christian tradition—since it seemed to foster a better understanding of the psychedelic experience. As the late Martin Fortier has emphasized, "the Indo-Tibetan tradition in particular addressed the philosophical and psychological questions associated with altered states of consciousness… in great detail.” In a 1967 article, the German psychiatrist Hanscarl Leuner explained this pursuit as follows: “The therapeutic mechanism does not correspond to any of our current psychological concepts. … Practitioners have no choice but to use these old concepts to interpret the results of their therapeutic trials.”

Anaïs Nin

Among the intellectuals whom doctors consulted in an effort to improve their understanding of the effects of LSD was Anaïs Nin (1903–1977). The French writer owes her fame to the publication of her diaries, which she began writing at the age of 11 and continued for her entire life. They offer a deep insight into her private life and her romantic, artistic, and intellectual relationships. Nin had ties with various psychoanalytical communities and, in particular, with Otto Rank, who was her psychoanalyst. In the fall of 1955, she took part in an LSD experiment conducted by the psychiatrist Oscar Janiger in which a musician and a biologist also participated.

Nin’s account of her experience appears at the end of Volume 5 of her Diary: “Gil Henderson, the painter asked me if I wanted to participate in an experiment because Dr. Janiger was hoping a writer would be more articulate about the experience.” She goes on to describe the session in some detail:

“It seemed strange to be coming to a psychiatrist’s office for such an adventure. Dr. Janiger took Gil and me into his private office, which was lined with books and very dark. I had little time to form an impression of him, for he immediately dispensed a number of blue pills, five or eight, I do not remember, with a glass of water. Then he conducted us to the waiting room, where the biologist sat already with a pad on his knee, pen in hand.”

She recounts how “all rigidities disappeared. It was as if I had been plunged to the bottom of the sea, and everything had become undulating and wavering.” The experience was peaceful, radiant, and pleasant: “My body was both swimming and flying. I felt gay and at ease and playful. There was perfect connection between my body and everything that was happening.” Marveling at these exotic visions, she was suddenly tormented by a thought: everything was appearing and changing too quickly, preventing her from remembering each scene, but most of all she realized that she would not be able to describe what she had seen.
“The walls turned to gold, the bedcover was gold, my whole body was becoming GOLD, liquid gold, scintillating, warm gold. I WAS GOLD. It was the most pleasurable sensation I had ever known, like an orgasm. It was the secret of life, the alchemist’s secret of life.” - Anaïs Nin

As she was lying down to catch her breath, she had a peak experience:

“The walls turned to gold, the bedcover was gold, my whole body was becoming GOLD, liquid gold, scintillating, warm gold. I WAS GOLD. It was the most pleasurable sensation I had ever known, like an orgasm. It was the secret of life, the alchemist’s secret of life.”

Later, as the effects of LSD began to wear off, she observed: “I felt I could capture the secret of life because the secret of life was metamorphosis and transmutation, but it happened too quickly and was beyond words. … Ah, I cannot capture the secret of life with WORDS. Sadness. The secret of life was BREATH. That was what I always wanted words to do, to BREATHE.”

She was very struck by her experience, and reflected on the nature of the LSD’s effects. According to her, the substance did not reveal an “unknown world” but rather allowed individuals to give in to their dreams and fantasies without the interference of the real world. LSD acted as a facilitator, allowing faster access to extraordinary experiences that could still be got at using other ways: “Obviously, by way of writing, reveries, waking dreams, and night dreams, I had visited all those landscapes.”

Finally, frustrated at not being able to recreate her LSD experience through language, Nin concluded that it had not been particularly positive. She became dubious about psychedelics’ widely assumed creative and spiritual potential, and wrote that, in fact, psychedelic trips had the potential to make individuals passive:

“So the drugs, instead of bringing fertile images which in turn can be shared with the world (as the great painters, great poets, great musicians shared their abundance with the unfertile ones, enriched undernourished lives), have instead become a solitary vice, a passive dreaming which alienates the dreamer from the whole world, isolates him, ultimately destroys him. It is like masturbation. The one who wrestles his images from experience, from his smoky dreams, to create, is able then to build what he has seen and hungered for. It does not vanish with the effects of the chemical. … And that is the conflict. The drug effect does not strengthen the desire to turn the dream, the vision, into reality. It is passive.”

Her stark rejection of the significance of the psychedelic state raises interesting questions. Notably, we find in her account an idea entrenched in the Western unconscious whereby forms of knowledge considered to be superior (artistic, intellectual, or spiritual) may only legitimately be accessed after a long and painful initiation. LSD and the other psychedelic substances were so many easy shortcuts. Any strategies meant to reduce the effort required to achieve such a superior state were considered pathetic and cheap. Anaïs Nin therefore judges Huxley’s psychedelic writings harshly: “Huxley was a scientist. These visions came from chemicals. They were controlled. There was no danger of a Rimbaud walking out of his poetic world.”

LSD also plays an important role in the sixth volume of her Diary. Following on her earlier ideas, she continues to examine the links between psychedelics and creativity, imagination, and religious belief. Nin had ties with some of the great personalities involved in psychedelic research, including Aldous Huxley, Betty Eisner, Timothy Leary, and Richard Alpert (Ram Dass), and she was critical of what she saw to be their overly scientific approach. She concluded that it was possible for artists and poets to describe the experience, but that these types of visionary works were not accessible to the majority of people, who preferred factual and clinical reports over “poetic niceties.” During the summer of 1963, she had written:

“No one had taught them [Western scientifically minded experimenters] to dream, to transcend outer events and read their meaning. They had been deprived of all such spiritual disciplines. It was a scientific culture, a technological culture. It was logical that they would believe in drugs, drugs of all kinds: curative, tranquilizing, stimulating and (logically) dream-inducing drugs… they were going in their own scientific way into their other reality. At one party, Leary discussed a statement he had made, that there was no language, no way to describe the LSD experience. I did not agree. I mentioned the poets; I mentioned Michaux; I mentioned the surrealists. All unknown to them. They were scientists, not poets. Huxley’s plain, precise, methodical report was more trustworthy. They were making links with ancient religions but not with literature, I felt.”

Anaïs Nin’s account may be somewhat of a caricature, but it nevertheless shows a semantic divide between cold and technical scientific language and the often-inexpressible fullness of a psychedelic experience. It also highlights the difficulty many non-academic intellectuals faced when describing the effects of these substances: their attempts were too far removed from the scientific culture of psychiatrists, who were the only recognized experts on these substances.
No one had taught them to dream, to transcend outer events and read their meaning. They had been deprived of all such spiritual disciplines. It was a scientific culture, a technological culture.” - Anaïs Nin

Betty Eisner dedicated one of her articles to Nin with the following: “To Anaïs Nin, who knows more about this than any of the scientists do.” Eisner recognized the significance of Nin’s insights and perhaps offered this dedication as a subtle nod to the need for nurturing these critical perspectives. Eisner was well aware of the complex network of players influencing the history of psychedelic science and its resistance to these critical, tempered, or even embodied perspectives.

Nin was familiar with the Tibetan Book of the Dead, but felt that Americans were not versed enough in poetry and myth to receive these Eastern concepts. She believed that Americans, with their thinking “blocked both by puritanism and by materialism” had no access to their inner world without the intervention of “a jolt, a shock, a violent tearing away from the earth” enabled by the consumption of LSD. She regretted that Leary and his followers adapted the language of Eastern religions without seeking in Western culture the means to describe these states (in surrealism, for example). According to her, because of their lack of sensitivity to poetry, Americans were unable to make sense of their psychedelic experiences, which led to negative experiences: “And what happened to those who had not become familiar with the meaning of the unconscious, of the dream, of creation through poetry, myths, psychology? They were frightened, confused; they were passive under the shock of dreams, visions, hallucinations. They could not integrate the visions with the art of living or the art of language.”
“The words that Westerners use to talk about these phenomena, which come from cultures far removed from their own, do not have the same meaning and can be pejorative or even sound ridiculous.” - Michel Perrin

However, concepts from Eastern philosophies, when adopted by Western science, had become devoid of their original meaning and lost their usefulness. Moreover, these borrowings had a very negative connotation to many at the time, as the anthropologist Michel Perrin explains: “The words that Westerners use to talk about these phenomena, which come from cultures far removed from their own, do not have the same meaning and can be pejorative or even sound ridiculous, all of which influences the understanding that the uninitiated may have.”

The use of this language mixing concepts from the Indo-Tibetan tradition with scientific terms largely contributed to the growing perception among the public, political actors, and the scientific community that LSD and the researchers associated with it were intimately linked to the formation of a counterculture threatening the established order. Consequently, the “psychedelic” vocabulary would have a decisive influence on the stigmatization of LSD studies and contribute to their eventual halt.

*From the article here :
 
Last edited:
INSTA114.webp



Women and diversity in the psychedelic community*

BIONEERS | 2019

Although the enormous growth of interest in and research on psychedelic substances’ potential for psychological healing and consciousness expansion is exciting, there are shadow sides of the psychedelic community that require attention. Women’s contributions to the field have too often been downplayed, and the abuse of women in some psychedelic underground circles has been a serious problem. Also, people of color, LGBTQ and other minority communities have been under-represented in psychedelic conclaves. A stellar panel of figures at the cutting-edge of inclusivity advocacy in the psychedelic community shared their perspectives on how to remedy these problems.

Hosted by Bia Labate, Ph.D., Executive Director of the Chacruna Institute, on the faculty of The California Institute of Integral Studies (CIIS), and Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies (MAPS). With: Emily Sinclair, leader of the Ayahuasca Community Guide for the Awareness of Sexual Abuse initiative; Sarah Scheld, a coordinator of MAPS’ MDMA Therapy Training Program; Monnica T. Williams, Ph.D., Associate Professor of psychology at the University of Connecticut; Sara Reed, MS, MFT, a study therapist in the Psilocybin-assisted Psychotherapy for Major Depression initiative at Yale University.

This discussion took place at the 2019 Bioneers Conference.

BiaLabate.jpg


BIA: My name is Beatriz (aka “Bia”) Labate. I am the Executive Director of the Chacruna Institute for Psychedelic Plant Medicines and a Public Education and Culture Specialist at the Multidisciplinary Association for Psychedelic Studies, also known as MAPS.

I have been drinking ayahuasca for 23 years. I’m Brazilian and I am grateful about that. It gave me the opportunity to encounter this brew and its traditions and to go to the Amazon and learn from Indigenous and mestizo people. I have a lot of gratitude for this path, which for me is a very sacred one, but I’m also a researcher and an anthropologist using scientific approaches to analyze this phenomenon.

The first thing I want to make clear is that sacred plants and most psychedelics are not “drugs” in the way our culture uses that term. They are not associated with pathologies and crime, and it’s been great that we have been seeing a cultural shift around this topic and that psychedelics are no longer demonized. We are, in fact, currently experiencing what some people call a psychedelic renaissance: a revisiting of the nature of these substances and compounds that looks at their healing potential and their benefits, accompanied by a very vibrant resumption of the research that had mostly been abandoned after the 1960s. So we have had a renaissance of studies, and MDMA and psilocybin are closer and closer to becoming regulated medicines, largely thanks to MAPS’ pioneering work.

At the same time that our understanding of the healing potentials of these wonderful plant medicines and psychedelics more generally and of these sacred plant traditions has grown, we also must acknowledge that there are shadow sides of this whole movement that have not gotten sufficient visibility and that have to be addressed. These include: sexual abuse by ayahuasca shamans and psychedelic-assisted therapists; a lack of attention to equal access to these medicines for historically disenfranchised and marginalized groups, such as people of color and the LGBTQ community; and the lack of recognition for women pioneers whose work has been frequently at the forefront of this research but who have been written out of the historical narrative.

This panel’s goal is to focus on these issues. If the psychedelic renaissance is to grow and be able to bring healing and benefits for humanity, it has to include everybody. We have to start discussing how to include everyone in this movement’s expansion. Our institute has been trying to do some work in this regard, to highlight the contributions of black and Indigenous women and people from the global south, and also people working not just in biomedicine but in other fields and forms of knowledge. We don’t have anything against white male, straight, psychedelic biomedical stars. We love them as well, but they have a lot of space already, and we want to create space for other voices.

I now pass the microphone to my dear friend and colleague Dr. Monnica Williams, who is on the board of our institute and who paid her own way to come here all the way from Canada. She is a clinical psychologist, specializing in cognitive-behavioral therapies, an Associate Professor in the School of Psychology at the University of Ottawa, Canada Research Chair in Mental Health Disparities, and Director of the Laboratory for Culture and Mental Health Disparities. She is also the Clinical Director of the Behavioral Wellness Clinic, LLC in Tolland, Connecticut. Dr. Williams has conducted clinical research on psychological and pharmacological treatments of OCD, PTSD, and anxiety disorders. Her research interests also include the role of culture and race on mental illness. She is an authority on obsessive-compulsive disorder, including sexual orientation-themed OCD (called SO-OCD or HOCD), racial trauma, and one of very few researchers focused on the inclusion of people of color in psychedelic medicine.

williams_monnica-e1557243878796.jpg


MONNICA: I’m thrilled to be here to talk about this. My little piece of this is going to be discussing racial equity and access as psychedelics go mainstream. Our mission at the Chacruna Institute is to provide public education and cultural understanding about psychedelic plant medicines and promote a bridge between the ceremonial use of sacred plants and psychedelic science. As a scientist myself, I often think in terms of anatomy, biology, and molecules, but I always have to remind myself that there’s a lot more to a human being beyond that—heart, and soul, and spirit. Our vision is a world in which plant medicines and other psychedelics are preserved, protected, and valued as part of our cultural identity, and integrated into our social, legal, and healthcare systems, and so I’m really excited to be a part of Chacruna.

I’m going to talk a little bit about racism today, and you may wonder how racism is connected to psychedelics. Obviously we all know that racism is real and alive and continues to impact people in a range of disenfranchised groups. Just about every economic, health and educational indicator shows that people of color are in far worse shape than their white counterparts in the U.S. There are of course individuals out there with racist attitudes, but the real problem is the pervasive, tenacious, deep structural racism in nearly all our society’s systems and institutions. And one of my areas of research is the impact racism has on mental health. There’s been a lot of solid research in the last 20 years that underscores how racism exacerbates just about every mental health problem that one can measure, and living in racist social structures causes its own form of PTSD. Racism is traumatizing.

And now psychedelic medicines are being advanced as potential solutions or at least treatment options to some of these mental health problems. And I personally do believe that the research is showing that psychedelic-assisted psychotherapy has the potential to heal or alleviate many types of psychological and emotional wounds, and not just MDMA, but psilocybin, iboga, and other substances as well. But people of color have not been included as research participants in these studies. In a recent review of research literature that we conducted in my lab, we tabulated 282 participants in a number of studies on psychedelics, and almost none were people of color.

Some of us in this psychedelic movement have been pointing out that black Americans are being left out of psychedelic research. My feeling that if white people are benefiting from it, people of color should too, and if we truly believe psychedelics can bring people together, we as a movement need to figure out ways we can do better. It seems pretty clear that psychedelic therapy is coming, but as it becomes legal and goes mainstream, it has to be available to all, and we will need, for example, therapists and healers of color who can take these therapies back to their communities to break stigmas and help people get well. We will need to explore whether psychedelics can help heal racial trauma. That is one of the things I’m dedicated to seeing happen, but psychedelic healing is only as effective as those who have access to it. Will these healing opportunities just be for white and elite people or for everyone? Will we simply replicate the oppression and exclusion in the larger society, or as psychedelics go mainstream, are we going to do this Right?

What would racial equity in this field look like? At Chacruna we put together a Racial Equity and Access Committee (there are also Women’s, Gender Diversity, and Sexual Minorities working groups) to promote inclusion and diversity by including the voices of those who’ve rarely been heard or included. So, to start, we want to give a prominent voice to, for example, women, queer people, Indigenous people, and people of color in the field of psychedelic science. Additionally, a social justice-oriented approach has to involve a more equitable distribution of funds and resources within the field and the transformation of systems and infrastructures to ensure fair access and equitable outcomes.

We need to start seeing diversity in our organizations at every level. We need to exemplify cultural humility and admit we don’t all have the answers. We can’t be experts in every culture. No one of us can which is why we need all of us. We need to develop and support culturally appropriate care because healing methods that are appropriate for one group may not be appropriate for another group. Community engagement is also critically important because for too long dominant structures have been imposing their idea of what communities need rather than participating and partnering with communities to hear their voices. We need to monitor disparities and, when necessary, call them out.

On our website, in the Chacruna Chronicles section, we have articles up on inclusion and diversity, and the pieces there include such topics as how white feminists can at times oppress black women, how unconscious white privilege affects psychedelic medicine, why psychedelic science should pay speakers and trainers of color, and how some groundbreaking people of color are making a difference in psychedelic healing (the catalyst for that was going to conference after conference and reading article after article and seeing no people of color reflected there, and asking where are all the people of color were and having conference organizers tell me, well, we just can’t find them. Well, now you can find them. We’ve put them on a webpage.) In fact, I see one of them here in the audience. Dawn Davis, a member of the Shoshone-Bannock Tribes from Idaho, a groundbreaking researcher on peyote conservation.

Another thing Bia and I have done to help amplify the voices of people of color and draw attention to this work is to be the guest editors of a special issue of the Journal of Psychedelic Studies on diversity, equity, and access in psychedelic medicine, and we will be including many people of color in the upcoming Psychedelic Liberty Summit we’re organizing for the spring of 2020. I encourage all of you who are interested in this to get involved. We can all make a difference in some way: you can volunteer, register for our newsletter, donate, follow us on our social networks, etc. We’re excited to welcome all of you to help to do this work because nobody can do it alone, and it’s an issue that affects everyone, and so everyone ideally will be part of the solution.

BIA: Our next speaker, Sara Reed, also came from far away, Connecticut, where’s she’s a therapist and the Director of Psychedelic Services at the Behavioral Wellness Clinic in the town of Tolland. She is the only black therapist in the United States who has treated patients in an MDMA clinical trial. Sara has expertise with a variety of anxiety ailments, including obsessive-compulsive disorder, PTSD, depression, phobias. She also works extensively with patients who have endured discrimination-related stress and trauma, helping them detoxify from internalized racism. Sara has also been trained in ketamine-assisted psychotherapy and is currently a therapist in a psilocybin study at Yale for patients with major depressive disorders.

reed_sara-600x600.jpg


SARA: Greetings to you all. It’s really an honor to be here. Special thanks to Bia for her commitment to this work and for bringing me here, and I also want to thank the coordinators, the organizers, volunteers, and founders of Bioneers for creating a space of visibility for visionary work. And last but certainly not least, I want to thank spirit for another opportunity to be a vessel and to share a small part of some knowledge I’ve learned within the field of psychedelic medicine.

I’m here to talk about equitable and inclusive practices in psychedelic medicine, and I want to touch briefly on how we can move from theory to actual practice, or, said differently, how we move from a “head space” to a “heart space.” One key issue is the tension between making sure we are doing sound, rigorous science in our clinical research and not losing the essence of the work, which is connection, witnessing, and honoring the possibilities and the power of the present moment.

I often do dedications to my presentations as a way to remind myself to bring my full humanness into the room. My dedication for this presentation is to a spiritual teacher who is teaching me how to be more present and to bring all parts of myself forward. And even though I don’t know her personally, I highly recommend each and every one of you to read Emergent Strategy by Adrienne Maree Brown. Her work has really impacted my life and has really helped guide this presentation.

To give some context and some background about me that’s relevant to this presentation, I was a study coordinator and a sub-investigator for the MAPS MDMA-Assisted Therapy Research study at UConn Health. Our site was focused on treating people of color and the specific traumas that face people of color, such as race-related stress and trauma. And unfortunately our site had to shut down before we could move on to the phase III clinical trials due to a variety of barriers, but even though we’re not an active phase-III site, we are still continuing the mission of advancing health equity for people of color in psychedelic research though advocacy work, though getting more in touch with the communities we serve, and by critically examining how race and power show up in psychedelic research. And these three topics—advocacy though storytelling, community, and understanding race in psychedelic—in the psychedelic context—will be the focus of my presentation.

At the MDMA-therapy study at UConn Health, we were under some pretty difficult constraints concerning the population that we wanted to serve. One constraint was that none of the therapists were native to Connecticut, and so we really needed to learn more about the community that we wanted to serve. We understood theoretically that we needed to build alliances with the movers and shakers in the community and to have buy-in, but that’s not easy to do as outsiders. We wanted to do community based work that wasn’t exploitative. We really needed to understand the heartbeat of the community. Another constraint is that in the clinical research realm, there are pretty strict deadlines and timelines that one has to adhere to, so we really had to be clear about the specific demographic-recruitment strategy we were going to use. We understood that “people of color” is a broad term, and that recruitment strategies for different racial groups might look different especially within the geography of Connecticut, so we were really thinking about all of these things as we were doing recruitment.

We reached out to a community organizer who helped us understand what was happening in Hartford, Farmington, Bridgeport, and the surrounding communities in Connecticut. From those conversations, we decided, given our time pressures, that it would be best for us to start with university students of color because there tends to be less stigma about seeking mental health services in that population and because they were likely to be more receptive to an alternative approach such as MDMA therapy. We gave talks on campus about MDMA therapy; we did a podcast called Can MDMA Treat Racial Trauma? Our approach was that people of color needed to hear about these experiences from people of color.

What the psychedelic medicine movement needs is inclusive community building. We need to build a multi-sector alliance that includes folks in drug policy reform and decriminalization, in harm reduction, in clinical research, and other organizations to sustain the working in related fields. Our work is connected. The milestones in our respective disciplines may look different, but we are all on the collective path towards healing and liberation.

We also need more diversity of people among those who hold positions of power. We need a greater number of black, brown, trans, queer, rural and neuro-divergent folks in those roles to help create spaces that actually represent and reflect multiple realities. In the psychedelic-assisted psychotherapy world, we need to recruit, retain, and support clinicians of color. There are not enough of us in the developmental phases of these drug-assisted treatments, let alone enough of us as researchers or clinicians. Without our voices in these spaces, we run the risk of creating treatments that don’t fit or exclude certain populations, or become elitist. And let me be honest: with the current systems and institutions in psychedelic medicine, it will be very difficult to advance health equity for many marginalized groups. Some parts of the current systems need dismantling and restructuring.

I participated in a psychedelic medicine and cultural trauma event in Kentucky, a day-and-a-half workshop that focused on the political and social factors that impact trauma and healing for people of color. I was able to expose people in my community to a very different way of being in their bodies and to talk about trauma and the effects of racism. Many people came up to me and were deeply appreciative and moved. We laughed, we cried, we danced, and we felt called to action to uphold our end of the sacred bargain as we fight for health equity for all people, especially those most marginalized in psychedelic medicine.

James Baldwin wrote: “Color is not a personal reality. It’s a political one.” Understanding that point is critical in the realm of psychedelic medicine. I’ll use a personal experience to illustrate. I took MDMA in a clinical context as part of the MAPS MDMA-therapy training. I was sitting on a couch, eyeshades on, music playing, two therapists in the room with me—the standard set-up for an MDMA clinical trial. As I started to feel the effects of the drug, my deceased grandmother appeared, and we shared a beautiful but brief moment. Tears of love flowed down my face and joy filled my heart. She carried me energetically to a place I knew existed but had never seen, a place that felt so familiar. I was a small part in this whole, but I finally felt like I had a place where I belonged. For the first time in my life, I felt free, me, a young, black woman, free.

unsplash-natalie-parham-bowqplMFeWQ-1200.jpg


In these sacred, precious moments, I was able to transcend the constraints of my political realities and connect to my humanness, the essence beyond masks and constructs. Soon enough, however, I started to notice the heaviness of my body, that my body was somehow slowing me down. I started to feel flooded with stories of my past and the ancestral past, my body reminding me of the fight it takes to stay alive in this black and female body. I had to learn how to sit with these stories in a way that I never had before. I had to be reminded that my political realities were just as present as my personal reality, and that my humanness is connected to both. So how do we move from theory to practice in understanding race? By moving past our theoretical understanding of race and courageously sitting in our racial wounds, by being present with our fears and intergenerational traumas no matter what our race is so we can all begin to heal and work towards healing from the wounds of racism and white supremacy.

As I close, I want to leave you all with one actionable item that can help you stay present and connected to your healing work, and specifically in healing from racism and white supremacy. Too often we get caught up in the liberation of others while forgetting to attend to ourselves, our own wounds and the parts of ourselves that have either benefitted from or been impacted by racism. So I ask, what’s something that you need to do to move towards healing that you’ve been putting off? What do you need to heal from in your own internalized racism? Take a second to think about it. Be honest about it, and sit with it. In the words of Adrienne Maree Brown, “The harder things are to say, the more necessary they are to say.” It’s time that you uphold your end of the sacred bargain and do the work. Show up in the way that is necessary and keep doing the work until you find your truth. We are all counting on you. The world needs your voice.

BIA: It’s my honor to pass the microphone now to Emily Sinclair, who is a Ph.D. candidate in anthropology in the UK and is part of our Ayahuasca Community Committee. She has been the lead of our initiative on creating awareness about sexual abuse in ayahuasca underground circles and has been working hard going to different countries to raise awareness and share the set of guidelines we created on this subject. Thank you for coming all the way from the United Kingdom to California, Emily.

sinclair_emily-sq-600x573.jpg


EMILY: I’ve been working for Chacruna for a couple of years. I’m an anthropologist and my main recent research has been on ayahuasca shamanism in Iquitos, Peru, which is the major hub of ayahuasca tourism, a Mecca for international ayahuasca use. That tourism and the spread of ayahuasca use globally have engendered a number of issues, so Bia and I came up with the concept of the Ayahuasca Community Committee, as a way to begin addressing key issues of concern across the global ayahuasca community, which of course includes a wide range of diverse communities working with ayahuasca in different contexts and settings.

One of the challenges of our work is trying to make it applicable for all of these often very different communities and to include people collaboratively in the work that we do. Our aim is to provide support and advice to participants and practitioners that address these issues, and one major concern in ayahuasca circles is sexual abuse of participants by healers and facilitators of ceremonies. Our first initiative was to produce the Ayahuasca Community Guide for the Awareness of Sexual Abuse. I was motivated to produce these guidelines due to my own experiences in Iquitos. I’ve lived there and worked there for the past six years, and I actually ran a small ayahuasca center for a time. I started to realize how many people were coming through that center and the wider region to work with ayahuasca in order to heal trauma caused by sexual abuse that they’d suffered in their lives. And then I was very shocked to discover that sexual abuse was also quite prevalent in the very setting in which they were seeking healing.

Sexual abuse in ayahuasca communities happens mostly to women, so we produced these guidelines addressing them mainly to female participants, but we also hope that they can be of benefit to everyone to help to raise awareness generally across the community that this is indeed happening. One key issue is that because there are so many new participants unfamiliar with ayahuasca rituals, there is a lot of potential for facilitators to take advantage of their ignorance to take advantage of them. In the guidelines we try to explain typical scenarios of abuse specific to ayahuasca settings and provide advice for ceremonial participants so they can avoid unsafe situations, and we seek to encourage awareness and positive action across the community to combat this problem.

The process of writing them involved collaboration with victims and survivors of abuse, long-term practitioners and participants across diverse ayahuasca contexts and communities, consultation with colleagues across the psychedelic community, and also with experts on sexual abuse. And of course we also drew on our own fieldwork experiences, anthropologists, and long-term participants in the ayahuasca community. As well as providing general safety guidelines such as checking out the healer and the context in which you’re going to drink through community contacts beforehand, speaking to people in the know, drinking with trusted companions, etc., we also created more specific guidelines aimed at empowering women by informing them about what is usual practice and what is not so that they can recognize red flags and feel more confident about speaking up if something doesn’t feel right. So, for instance guideline number four is: “It is not necessary for healers to touch intimate parts of your body or any area to which you do not consent.” Or number five is: “Ayahuasqueros do not require you to remove your clothes.” One of the main aims of these guidelines is to demystify the figure of the shaman. Another key issue we wanted to draw attention to is consensual sex between healer and participant. We found that many occurrences of abuse take place in this context whether the abuser has manipulated a participant or assistant’s trust and taken advantage of the uneven power dynamics between them. Another aim of these guidelines was to promote a sense of collective responsibility for this problem in our midst and to encourage collaborative action to combat it.

We also created a legal resources companion to the guidelines, which provides information about laws related to sexual abuse in popular destinations for ayahuasca in South America, and a list of helpful organizations where victims and survivors can seek support. These are available currently for Peru and Brazil online though our website via this link. I think this is a really important part of the work. I personally know of a couple of examples of women who have gone to the police in Peru to complain about sexual abuse and actually been laughed at by the policemen there which of course causes much more trauma, so it’s really important to know safe places where you can go should this happen.

Most people in the ayahuasca community were very supportive of the initiative, but I did experience some resistance. Notably, there was a prominent figure who tried to tell me that sexual abuse was no longer a problem in Iquitos, or in general, and that an insider organization called the Ayahuasca Safety Association was already set up to deal with the problem, should it occur. This is something I knew not to be true because I was closely connected to that group. So was demonstrative of the fact that the truth about sexual abuse in the community is being suppressed by some people either perhaps because they are complicit in it, do not want supposed outsider intervention, and/or do not want to draw attention to negative aspects of the ayahuasca community in the interest of protecting its reputation and their own livelihoods. This is a very dangerous attitude, and fortunately we seem to be moving away from that kind of behavior in addressing these problems in our midst.

I distributed the guidelines in ayahuasca tourist information hubs that included cafes and hostels as well as the Peruvian Tourism Agency. And I spoke to a lot of newcomers in the region who were new to ayahuasca and were very surprised to learn that sexual abuse occurs in this context, and this is very common. It’s the main reason this information needs to be available to these new participants.

I also had formal and informal conversations about the guidelines with local practitioners and Westerners in the community including ceremony leaders, participants, local artisans and local healers. And sexual abuse is recognized as a big problem in the wider society as well as in ayahuasca contexts. Local people especially emphasized the importance of education to address this issue. I also met with the Ministry of Tourism and the British Consul in Iquitos. One of the great successes of this project is that the British Embassy in Peru has taken an interest in the guidelines and has actually disseminated them throughout all the western embassies aiming for them to be used as safety advisory information for travelers to Peru. And I’ll be attending a meeting at the British Embassy in Peru next month to discuss these issues with representatives from all the relevant organizations. The British Consul pointed out to me that governments are becoming less interested in trying to dissuade people from drinking, probably because it didn’t work, and more interested in trying to ensure their safety while doing it. That’s a really positive development, and it shows that ayahuasca-related practices are becoming more widely accepted.

I have given presentations in local schools and had great discussions with Peruvian students which addressed sexual abuse in general, gender inequality issues, as well the growth of ayahuasca tourism in their community. It was really interesting to hear their points of view. Many of them consider the tourists who come to drink ayahuasca as “crazy gringos.” I think that more education of this kind with local and young people in the community would be welcomed and beneficial for all.

This process has highlighted for me a few key points. Firstly, I think it’s essential that we acknowledge the abuse in our midst. Abuse is happening within healing communities as much as beyond them in the larger society. We cannot overcome this problem if we choose to ignore or suppress it. Community self-regulation involving communication and collaboration across cultural and gender boundaries is also essential for combating this and other safety issues in medicine and healing spaces.

I think the inclusion of men in this conversation and in this effort is also particularly important. Otherwise we run the risk of creating further segregation, which of course is one of the underlying causes of abuse. So on that note, in ayahuasca contexts specifically and perhaps beyond them, the division in many cases between Western and Indigenous and mestizo Amazonian people, and the lack of understanding that exists between them is a huge issue and a causal factor of abuse of many kinds which goes both ways. In Iquitos and more widely there is a great need for improved cross-cultural communication and educational initiatives that would serve both Amazonian and Western groups and encourage reciprocal relations between them. We’re currently formulating projects to be based in Iquitos that will try to address these issues for which we’re currently seeking funding. So if you’d like to come and speak to me afterwards to find out more about those projects or visit us at the Chacruna booth, that would be very welcome. We’re also selling plant products and textiles from the Iquitos region there, and those sales benefit the local people in that community as well as helping to sustain Chacruna’s work.

BIA: Following this thread about the importance of addressing the shadow sides of psychedelics, we are now going to hear our last speaker, Sarah Scheld, a Training and Supervision Associate for MAPS' Public Benefit Corporation. Sara helps coordinate and develop curriculum for MAPS’ MDMA Therapy Training Program and recently collaborated on a Code of Ethics for MDMA-assisted psychotherapy providers (that was published in the MAPS bulletin issue that I had the pleasure to be the guest editor of, Women in Psychedelics). Her work focuses on trauma awareness, somatics, and the ethical use of psychedelic medicines to help heal people, communities, culture and the environment. Before I hand it off to Sarah I want to mention that MAPS faced a challenging situation involving an incident of therapeutic abuse and responded by stepping up and insisting on clear accountability and transparency, and I think that’s worthy of praise.

scheld_sarah-1-600x600.jpg


SARAH: Thank you, Bia. Thank you, Bioneers. It’s amazing to be back here. Thank you to my co-panelists. I’ve been really grateful to collaborate with most of these women doing a lot of behind-the-scenes work with the MDMA Therapy Training Program that teaches therapists to facilitate MDMA-assisted psychotherapy mostly as a treatment for people with post-traumatic stress disorder.

I want to share the caveat that I’m not here specifically as a representative from MAPS, and will not be talking a lot about the MDMA Training Program in detail. I’ll mostly be speaking about my own experience and how my interest in psychedelics developed into a passion for trauma awareness and trauma resolution, as well as the role of the body in personal and cultural healing.

When I started working with psychedelics in 2010, I was in the underground psychedelic scene of New York City in both ceremonial and recreational settings, and there I had quite a variety of experiences, some healing and illuminating and some challenging. On the challenging side were experiences that were facilitated by, for example, untrained and unskillful basement shamans, and some experiences with actual predators, men in positions of power in the psychedelic community who attempted to, or in some cases did, cross sexual boundaries with me. At the time I had graduated with a degree in film, and I was working as a production designer, and I was very devoted to my own creativity, but I’d also struggled with a severe eating disorder for several years as well as chronic migraines and no menstrual cycle, but at that time no medical professional had ever attributed my symptoms to trauma. I was even making experimental films about sexual violence while on another level abusing my own body.

When I started experimenting with psychedelics, I was reminded of this spiritual connection to nature that I’d known deeply in childhood, but I wasn’t yet aware that I was being drawn into this work to address trauma. I wasn’t aware that the issues I was navigating were related to a history of sexual trauma. I wasn’t thinking about the fact that in college I had been drugged and date raped by a stranger, or that I had experienced this trauma in an altered state of consciousness. By opening up to psychedelic experienced, I was unconsciously trying to re-constellate and heal that trauma, but I was ending up in situations that were actually replaying it and were actually re-traumatizing. This was a period of spiritual opening for me but also of confusion and I would say of spiritual emergency. I had really murky boundaries and experienced a lot of symptoms—trauma symptoms reemerging—becoming withdrawn, and ungrounded, and I started developing addictions to other substances.

Not long after my home in New York was destroyed by Hurricane Sandy, I chose to move to California in 2013 to pursue a master’s in East-West psychology at the California Institute of Integral Studies—I see a couple of my alums are here—out of a strong interest in psychedelic healing work and out of a need for my own personal healing. And there were a couple of things that I encountered during that time that really changed my approach to how I was healing with these medicines. One was I began to work with MDMA-assisted psychotherapy in a one-on-one context with a really skillful underground therapist, and through that work I began for the first time to realize that I have trauma and that MDMA can be a powerful ally in trauma healing. Through this work I gradually began to work not only with the trauma of this rape in college but to uncover completely repressed memories of early childhood sexual abuse. I understood that a lot of my behaviors and addictions were really a trauma response, and I also realized that my childhood interest in art and in nature had emerged as a way to distance myself from those traumatic experiences.

The experience of safety with my guide during this journey also taught me about the importance of the container for this work—the set, setting, and quality of the human relationship. All of this is context for why I’m so interested in the ethics of psychedelic spaces. In recent months I had the great opportunity to collaborate with many others who are more deeply versed in this realm of work on a code of ethics for MDMA-assisted- psychotherapy providers working on MAPS protocols. And it’s through my own experience as a trauma survivor that I can see how people with trauma could have difficulty holding their boundaries with unethical practitioners.

As you can imagine, psychedelic work carries heightened ethical challenges for practitioners including very strong transference and projections that can affect both practitioners and participants. Repressed sexual feelings can arise in these spaces, and in American culture many of us use substances to let our guards down sexually. It’s such a common phenomenon, and so it’s just really natural that repressed sexual feelings would come up in altered states.

I’m not going to go deep into the ethics of MDMA work but want to highlight one aspect of it. In deep experiential or psychedelic therapy, and especially in trauma work, it’s not just about the psychedelic substance that’s doing the healing work. It’s really the relationship that’s a key agent of healing. A participant in a psychedelic session can experiment with new ways of being in a relationship, feeling a new sense of safety or self-expression, or a capacity to set boundaries, and then they can internalize this experience as embodied knowledge and rewrite new neural pathways such as: “Oh, safety is possible,” or “I can be received by this person who looks different from me and whose difference I might have mistrusted before.” And for myself, the more I work with medicines, it’s more about which people I’m sitting with to have these experiences and what their values are rather than about which substances I’m using.

I’m interested in this topic of ethics not just for the MDMA work but because, as all of us here are, I want to raise awareness in this wider community and protect people having experiences in any setting above ground or underground. And while I’m working professionally within a medical model, I do believe that people should have the right to have these experiences and to be held by community in a safe way and in a container that’s appropriate to their own personal and cultural needs. And I’m really grateful to see this expansion of dialogue around ethics—sexual ethics and ethics around cultural differences in this community in the past couple of years.

Another key piece of my own healing has been the study and practice of somatics and somatic therapy. Around the time that I moved here, I started studying these somatic- psychotherapy methods—Hakomi and Somatic Experiencing—which more so than other therapies are interested in tracking and working directly with the felt sense of the body alongside emotional processes. These approaches, particularly Somatic Experiencing and also MDMA-assisted psychedelic therapy, all work on the principle of allowing the body to complete interrupted trauma responses, to move towards comfort, to do what our bodies are actually as animals designed to do but might have been prevented from doing in the moment of a traumatic event. These methods help people move beyond the narrow story of trauma to a sense of their organic self, and really through trusting the intelligence of the body to release, and self-regulate, and regulate in relationship.

shutterstock_101206282_1200.jpg


As I studied trauma therapy, I also learned about the concept of titration, going slowly and managing emotional processes in bite-size pieces small enough that they can be contained by our nervous systems. With titration, you build safety, touch into trauma but pull back if it’s too much for the nervous system to handle. And with that, I started to realize that in my earlier psychedelic work I had been doing the exact opposite of titration. I’d been blasting myself open and actually staying caught in a trauma cycle. Being—for example, in ceremonies with people screaming all around me was actually just overwhelming for my nervous system and was preventing me from being able to do the deeper work that I needed to do.

I’m so grateful for somatic practice because my psychedelic experiences were really ungrounded without it. I was chasing altered states as a means of chaos seeking, or alternatively as a means of spiritual bypass. And I now realize at the time I was also taking in a dominant narrative about how to use these substances. A lot of psychedelic research tends to overwhelmingly focus on ego-dissolving experiences, these kinds of cosmic- oneness experiences when we’re not connected to the body, and I think in part this tendency is because a lot of the writing in our field still comes from older, white men that tend to privilege mystical experience and bypass the body.

Also our understanding of trauma in neurobiology has vastly advanced since the ‘60s and ‘70s when therapy in psychedelic work both tended to explore catharsis and this idea that we have to break through repression. And while catharsis and ego-dissolving experiences have their place, what I’ve learned from my own experience and from witnessing other trauma survivors is that some of us actually need to rebuild our egos rather than shattering them.

Through somatic work I realized that my unconscious and my shadow really live in my body, and once I started studying through these somatic practices how I was dissociating, I realized how shockingly disconnected I’d been from bodies, especially my body, since I was quite young. I’d learned to dissociate at a very early age as a way of coping with extreme physical discomfort I had experienced, and I had turned, as others do, this abuse against myself into addiction.

Thankfully we’re learning more about how addiction is rooted in trauma, and there’s been a real failure until now in Western medicine to recognize this, and I have felt personally failed by that. Eating disorders specifically are rooted in trauma, very often, sexual trauma. And I’ve been learning about this from my colleagues who are developing a research study sponsored by MAPS to explore the potential of MDMA-assisted psychotherapy in the treatment of eating disorders. I’m really excited about what I think can be really groundbreaking work. So with somatics, all of my personal work gradually became about my own embodiment, and this has been a really slow process. I’ve been humbled again and again to be reminded that psychedelics are not a panacea and that healing developmental trauma takes a long time. It’s difficult work to become re-sensitized to the world and to learn to self-regulate.

Embodiment work begins with learning safety through relationship, and for me community, in particular healing friendships and healing partnerships, have been more influential than any therapeutic relationship. Throughout this process I began to think that if I had a trauma history without knowing it and was dissociated without knowing it, what might that say about the general public?

I’ve become really interested in looking at how trauma symptoms show up in our culture and how trauma awareness and trauma resolution play a part in collective healing. Psychedelics are repressed precisely because they teach us about trauma, and our culture has done a lot in our history to deny trauma, and we tend to look away from it and dissociate from it unless we absolutely have to look at it. It’s notable that it was only after the Vietnam War and the Civil Rights Movement that PTSD became an official diagnosis. And so now as a student of trauma work, I see trauma symptoms everywhere, in climate denial for example, which Benjamin White more aptly calls “climate dissociation.” Dissociation is a trauma response in which one leaves the body when experience is overwhelming. I’ve also been unpacking the relationship between dissociation and whiteness and privilege, and seeing privilege as this dissociative mechanism that protects people from dealing with their trauma or others’ trauma. And how do you work with someone who’s dissociated? Not by ideologies, or rationalizing, or yelling, but by beginning with safety, and relationship, and resource, and asking what they care about.

I really see that trauma work brings people out of old survival strategies and back to the body into the present, and in this way, healing trauma is a crucial task in the broader work of responding effectively to the needs of our time. And I really appreciated Eve Ensler this weekend telling us to trust our bodies. It’s that simple. I’ve become really interested in the work of people focused on the intersection of somatics and social justice, organizations such as Generative Somatics and people such as Resmaa Menakem who work specifically with racialized trauma in the body and explore how our bodies and bodily interactions are shaped by systems of oppression and how we tend to perpetuate those systems in our relationships. They also show us we have the power to reshape ourselves and to reshape our interactions. This is an important piece for me when it comes to thinking about ethics—understanding our bodies within the greater ecology of our relationships and understanding our cultural shaping. Working with trauma is complex and confronting because it asks us to face all the intricate connections of trauma stories, intergenerational trauma, the whole ecology of trauma, and how we participate in it.

Coming out of dissociation from being a victim of sexual trauma has also made me feel the abuses I’ve perpetuated against the Earth’s resources and the ways that I’ve been complicit with suffering, or blocked from empathy. So for practitioners of psychedelic work, how might the oppressive structures we unconsciously carry affect our ability to support the empowerment of someone in our care? Kylea Taylor, author of The Ethics of Caring, which is a really amazing book on the ethics of non-ordinary-state therapy, writes, “We professionals are a combination of our programming by cultural paradigms and the deep self-reflective work we’ve done to discard whatever of the mainstream culture is not consonant with our authentic selves.” We have to work hard to see through and transform the oppressive structures underlying the systems that we’re working with.

I’ve been appreciating the way the author Ta-Nehisi Coates frames cultural semantics, that as a collection of living bodies, we actually have a collective cultural body, and the cultural body is also processing trauma, so we have to also work with this collective nervous system. He says that in effect we have to approach our activism, our cultural-body healing work with a somatic understanding of the world. It has become really important for me to think about that in movement work.

I’ll end by re-emphasizing the idea of titration I mentioned earlier, the importance of staying in relationship, staying kind and honoring the principle that growth happens when it can be held within the capacity of the nervous system. I want to express a lot of respect and gratitude to the people who have held these traditions alive for many generations in spite of colonization and to the lineage of underground practitioners who have also kept the flame alive, and to so many people who have dedicated decades to patiently working with the complex legal barriers to push these treatments and to make these treatments accessible to make it so much easier for young people like myself to join this work now. Thank you.

BIA: Thank you so much, Sarah. Before we open it up for questions and answers, I want to mention another minority we haven’t discussed, which, ironically, is something very dear to my heart, the LGBTQ community, which I’m part of. The Chacruna Institute organized a conference last June called Queering Psychedelics which aimed to explore the intersections and overlaps between the queer movement and the psychedelic movement, both historically but also looking into native traditions and the idea of two spirits, and thinking on how psychedelic therapy or shamanism could help these special populations that often suffer high levels of depression, anxiety, body dysmorphia, addiction, and stress. We addressed such issues as the special needs of these populations and how psychedelics might help them, and what special contributions this community could make to the larger movement. It was a wonderful meeting, and we just published a document called “10 Calls to Action Toward an LGBTQ-Affirmative Psychedelic Therapy” on our website, which I recommend highly.

I just also want to thank my wife: she has had a lot of patience because I took eight years to be able to say those words. It was a coming out for me as well, and I want to thank California because it’s much easier to be queer in California than in Brazil. I have a few cousins and aunts who voted for Bolsonaro who is incredibly homophobic among other problems; he makes make Trump look like a really nice guy. I think it’s very important that we embrace this topic of gender minorities and bring it to the heart of the psychedelic movement because it’s so overlooked. Very little attention is paid to this topic. So I want to invite you all to go to our website and read these materials.

I also want to share a story that illustrates what hard work we all have to do. We held an event called Women in Psychedelics, and one of the participants said the N word. I did issue an apology, but it definitely was not strong enough a reaction, and Sarah Reed, who has been so generous in joining us here today, was very upset and left the event. We didn’t know each other at that point, but she was a guest at our event, and she wrote me a very nice email explaining why that incident was so upsetting, and I felt really bad. I reached out to Sara and to Monnica to ask for their help and guidance in figuring out how to address what had happened. After millions of zooms, emails, and phone calls, we ended up issuing two apologies, including a collective one on behalf of all of the women there because silence is compliance with white supremacy, and everybody was silent. Nobody said anything. And it has been a very tough process, and I got very upset a number of times, but my wonderful team and friends told me to hang in there. And a few months later we’re all here sitting on this panel talking about these critical issues. I’m sharing this personal experience to show how we can grow together, and that hard conversations can bring healing and advancement, and I’m so proud to have Sara and Monnica as new friends, and I’m so thankful that they so graciously accepted my invitation to participate in this panel.

AUDIENCE MEMBER (AM): What can be done to get more participants of color in psychedelic therapy treatment?

SARA: I hesitate because I think the way that the psychedelic-medicine field is now, it may actually be more harmful for people of color to participate. Unless there’s a critical examination and understanding of race and power and how they play out in psychedelic-assisted therapy specifically, the set and setting might just not be right for many people of color. And there are other impediments as well. There are so many barriers we have to break down. In many communities it’s not okay to ask for help. There’s not enough mental health literacy for black folks particularly. They often don’t understand their symptoms as trauma, for example, so education will have to be a huge part of the movement.

AM: How might specific communities be able to have more autonomy over their medicines and healing processes and have more of their own people become licensed or trained in how to do this well to overcome the strict, clinical barriers that are in place now.

MONNICA: Right now those who are being trained to be psychedelic therapists are a very exclusive group in a lot of ways. There isn’t a lot of representation of people of color, and so one of the things we’ve been passionate about is bringing in more people of color to get this training, so I can go into my community and have clinicians who are a part of my cultural group administer this therapy to me in a safe, familiar container, and right now that can’t happen. I don’t think that’s an unreasonable thing to ask for.

BIA: I want to say that in the ayahuasca world one of the main problems is that traditional networks of power and of authority are being dissolved. So traditionally shamana operated within a community with authority structures they had to answer to. With globalization and the explosion of ayahuasca use and tourism, this tends to be dissolved, and you have, for example, a lot of itinerant shamans who aren’t accountable to anyone. So I very much encourage people that want to get engaged in this phenomenon to create supportive communities. The commodification of ayahuasca is posing many challenges. We just put out a document called Commodification of Ayahuasca: How Can We Do Better? One of our main recommendations is that people who want to use this medicine constructively should try to form communities around the medicine, communities that feature accountability and self-regulation.

SARAH: I just fully believe that certain kinds of community-based traumas, because they happen on a community level, are better held in community, and there are already examples of that in this work, and one that’s happening in a legal way is there’s a study at UCSF conducted by Brian Anderson called Researching the Effects of Psilocybin-Assisted Therapy in Long-Term AIDS and HIV Survivors, and they’re actually doing group preparation and integration work so that these survivors can be in community with other survivors. And for certain conditions such as PTSD, it’s helpful to have someone who’s deeply trained to work with that kind of material.

AM (addressed to Monnica): What specific therapy would you recommend for sexual abusers?

MONNICA: That’s a really important question and a hard one because abusers are so stigmatized that often they can’t come for help, and often abusers were abused themselves. Abusers need help like everyone else, and I think it takes a special kind of person to work with an abuser, and at the same time I think we do need a shift in our social consciousness to allow us to also approach abusers with compassion so that they can get the healing that they need which will then help everyone.

BIA: We have to wrap it up, but thank you all so much for coming. This was a really great session. If you can, I urge you to support the work of the Chacruna Institute and of MAPS, which is on the frontlines of so much of this work.

*From the article here :
 
Last edited:
960x0.jpg

The Aphrodite Health Executive Team

The first psychedelics company ‘for women, by women’

by Amanda Siebert

The psychedelics industry is expanding rapidly, with dozens of new companies emerging over the last two years. While psychedelic drugs and the mental health issues companies hope to treat with them are experienced by people of all races and genders, the vast majority of psychedelic executives don’t reflect that diversity.

The latest company to introduce itself is changing that, with the goal of providing women with a more specialized approach to both healthcare and psychedelics. Founded by a group of four women from around the world with backgrounds in biopharma, tech, cannabis, and the consumer goods industries, Aphrodite Health is focusing on a realm of medicine other firms in the space haven’t yet touched on.

Female-focused therapeutics for mental health

“First off, we are for women, by women,” says co-founder and CEO Tesla La Touche, an Afro Indigenous specialist in surgical, biopharmaceutical and clinical therapy technologies, who has worked with several multinational companies throughout her career including Roche and Johnson & Johnson. She comes into the space with both a professional and personal understanding of how existing treatment options for women’s health issues are limited.

La Touche’s interest in psychedelics was sparked by her own experience following a debilitating surgical procedure in 2006 that left her with severe trauma and extreme pain. “I was looking at alternatives to opiates,” she says. “Because I worked in an orthopaedic corporate medical technology environment, I already knew that traditional pain management wasn’t going to be my path.”
La Touche began exploring the combination of psychedelics and advanced clinical therapies, which she says, “started me on the journey of wanting to take a stance for more innovative tools in this space, so that we could offer them to others” — especially to women in her age group.

The word ‘kinetic’ comes to mind

The first all-female founded psychedelics company, Aphrodite Health is also the first firm in the space to address the development of a female-focused therapeutic for mental health. La Touche says her team’s commitment to justice, equity, diversity and inclusion, and access is “baked in” to its vision for drug discovery and clinical research, with the intention to “get a lot more right in the way that we approach women’s health research and market uptake,” says La Touche, than what’s currently being offered to women via traditional medicine and the cannabis industry.

Other founders in the company include chief operations officer Victoria Armstrong, chief strategy officer Olivia Mannix, and chief of staff Vestaen Balbuena. Armstrong is a serial entrepreneur with international experience in health and tech startups, while Mannix is a business strategist who has started several companies in the cannabis and psychedelics spaces, including Cannabrand. Balbuena is focused on the incubation and scaling of startups in health, tech, and consumer goods, and is also a senior associate of funding at The Conscious Fund.

“We galvanize women from around the world. I think we represent women culturally, intellectually, philosophically, geographically — and anecdotally, we get it,” La Touche says of the Aphrodite team. “We have really looked at curating a team of women that are willing to play to their genius.”

The CEO has worked with all-female teams before and says she’s fond of the working dynamic a group of women can create together: “The word ‘kinetic’ comes to mind, because to be kinetic is to be in flow. That summarizes our collective process. We are specifically inspired around metacognition, so to be in the will and application of what we know, all the time, and it definitely makes things feel more at ease.”

Going public?

The company’s announcement came with the news that it will approach the industry two ways, first with a psychedelic drug discovery program, and second, with an over-the-counter product that should be available to consumers sometime in 2022. While La Touche couldn’t provide an exact timeline, she did say that Aphrodite Health has plans to go public.

The first product in the company’s pipeline will intend to disrupt the antidepressant market and provide a treatment solution for women who suffer from sex-related mood disorders during menopause. La Touche says the mission for the Aphrodite team is to elevate women’s health and women’s autonomy in the emerging space, offering a more personal approach to treatment for this and eventually other women’s health issues.

“We have a mission to elevate women’s health and our autonomy in psychedelic medicine discovery,” says La Touche. “Our vision is rooted in evidence-based functional and personalized medicine, and that, I think, is the biggest game changer… it’s time for the market to self-correct, and deliver more options for self-directed care, as a general rule of thumb around our approach to healthcare.”
 
Psychedelics-and-Pregnancy.png



Psychedelics and Pregnancy ~ A look at safety, research and legality

by Rebecca Kronman | Psychedelics Today | 29 Sep 2021

Psychedelics and pregnancy is a highly controversial and often unspoken topic. But beyond the stigma, what does the research, law and culture say?

As she had done many times before, Leticia Pizano sat in ceremony with her medicine sisters waiting to feel the effects of the four grams of magic mushrooms that she had ingested. An experienced journeyer, Pizano found it strange that 45 minutes later she began vomiting, an effect she was unaccustomed to so early in the trip.

“The medicine just showed me that I needed to get that out of my body because I was with baby,” she tells Psychedelics Today.

Still, the mushrooms took effect and led her on a trip she described as beautiful and empowering. The experience enabled her to form a deeper bond with her unborn child. “There’s just a different connection with her; almost non-human,” Pizano says of her daughter, now six months old and the youngest of her twelve children. Since her daughter’s birth, Pizano has brought her “medicine baby” to every ceremony she has attended.

For Pizano, participation in community-based ceremony was a motivating factor for her use of entheogens, and her use during pregnancy was consistent with cultural norms—she is a member of the Second Fox and Kickapoo tribal nations, where partaking in ceremony that includes plant medicine sacraments spans throughout the lifecycle. For most non-Indigenous people, such participation would be unusual and likely stigmatized, perhaps viewed as dangerous or irresponsible.

Yet, as psychedelics enter a more mainstream era, non-Indigenous birthing parents are relying on them as tools for wellness and even lifesaving measures to address treatment-resistant depression, anxiety, post traumatic stress disorder and addiction. Our current paradigms for substance use during pregnancy do not account for these new developments, and examining them with a thoughtful, critical lens may be required to accommodate the myriad ways our culture has shifted towards relying on these substances for well-being.

Information, misinformation and disinformation ~ Research and public health information on psychedelics and pregnancy

Just as with other psychotropics like antidepressants or anti-anxiety medications, birthing parents and their healthcare providers need to evaluate existing information on psychedelics and pregnancy to make informed decisions about whether to continue using them during pregnancy. But seeking information on the web yields few results. And what little information does exist on the topic is often confusing, incomplete and misleadingly shaped by the War on Drugs.

The American College of Obstetricians and Gynecologists offers a blanket statement recommending the cessation of all marijuana use. Other psychedelics are similarly classified into a category of “substances that are commonly misused or abused”, a classification that bears the markings of bias and misinformation. According to the Global Drug Survey, we know that many psychedelic users ingest these substances in a safe, prepared and informed way, and according to longtime drug researcher David Nutt’s book, Drugs Without the Hot Air, psychedelics like mushrooms and LSD are not inherently addictive.

The March of Dimes, a research and advocacy group for mothers and babies, offers an unsourced page last edited in 2016 on their website that reads: “Street drugs are bad for you, and they’re bad for your baby.” The psychedelics included in this category are marijuana and ecstasy. This broad categorization fails to account for the therapeutic applications of these substances. It also excludes critical factors like set, setting and dosage, all of which make a significant difference in a psychedelic user’s experience.

Mother to Baby provides more nuanced and specific information on psychedelics, but contains obvious biases such as suggesting that “people who use LSD might also have unhealthy lifestyles.” They also include misleading, inaccurate and fear-based information including the suggestion that people may mistake magic mushrooms for poisonous mushrooms.

These blanket prohibitions are largely based on the absence of—rather than the presence of—information about how a substance will impact a growing fetus. The medical research canon contains very little information about the effects of these substances during pregnancy, and substantial obstacles exist for this research to take place at all.

Due to ethical and safety concerns, “The research we do have on pregnancy in general—let alone pregnancy with psychedelics or plant medicine—is minimal because we don’t do research in pregnancy for the most part,” says Jessilyn Dolan, a registered nurse, herbalist, hemp farmer and member of the Board of Directors for the American Cannabis Nurse Association.

Aside from ethical considerations, says Dolan, another challenge is measuring the long-term health impacts to the child of just one substance due to the enormity of confounding factors. For example, is a person who consumes cannabis edibles during pregnancy also consuming caffeine, alcohol, or prescription medication? How might these substances along with the birthing parent’s diet and lifestyle impact the long term health outcomes for the child? And how might the child’s environment, including exposure to toxins, food insecurity, poverty or traumatic life events, play a role in their health as well?

“When we look at pregnancy, breastfeeding and chest feeding and then doing longitudinal studies around kids, we have so many factors working against us to make that research really legitimized and standardized,” says Dolan.

Of the existing research on this topic, most is either outdated or based on small sample sizes. As legal restrictions on these substances shift, this may change. But information about the safety of ingesting substances during pregnancy is still scant, inconclusive and conflicting.

A study from 1968 on nine children exposed to LSD-25 in utero—the only study that we could identify on the topic—found elevated levels of chromosomal damage compared to a control group. However, none of these babies exhibited any birth defects. This study, with its very small sample size, has never been replicated. It also did not look at long-term outcomes for these children, rendering the results limited in value.

Similarly, an often cited and widely circulated study from 1994 compared 24 newborns exposed to cannabis to 20 who were not; results at 30 days showed that the cannabis-exposed babies actually scored higher on measures of alertness, were less irritable and had better reflexes. But this study, again with a small sample size and never replicated, did not take into consideration the many confounding factors that could have contributed to the results. For example, the study took place in Jamaica where cannabis use during pregnancy is a common practice and is not stigmatized. In addition, the heavier cannabis-using birthing parents were also more educated, more financially stable and had fewer other children to care for, all of which could have impacted outcomes for their babies.

More broadly, research on prenatal drug exposure is often mired in biases. In his book Drug Use for Grownups, Dr. Carl Hart details several problems associated with brain imaging research on people exposed prenatally to drugs. "It is easier to get findings published," he says, "when they are consistent with the widespread notion that drug use is bad for the developing fetus. In addition, Hart writes the findings are almost never replicated and researchers often ignore their own data in order to draw conclusions that reflect their own biases."

Still, experts in the field like Amanda Fielding, executive director of the Beckley Foundation, a UK-based NGO that funds psychedelic research and supports policy change, remain hopeful about the prospect for more research on the topic.

“Scientific exploration could be carried out using animal models, or using naturalistic surveys to get answers from people who are already using or have already used psychedelics during their pregnancy,” Fielding says.

Keeping a close watch on pregnant bodies

Weighing risks of physical harm to the fetus against physical or mental health outcomes for the birthing parent is one framework for decision-making of this kind. But these calculations are not the only ones a birthing parent will have to assess. Most people who have experienced pregnancy will be familiar with an increase in monitoring by friends, family and even strangers who may feel entitled to comment on body changes, touch the pregnant person’s body without permission, or offer unsolicited advice or opinions on what the pregnant person ingests. Using psychedelics openly may create social stigma and isolation; the anxiety and stress that those conditions create may pose an additional risk for pregnant people.

Pregnant people are also monitored more closely by state and healthcare agencies. The American Academy of Pediatrics and American College of Obstetricians and Gynecologists recommends screening a pregnant person for drugs when they enter prenatal care. Twenty five states and the District of Columbia require healthcare professionals to report even suspected drug use, and eight states require them to test for prenatal drug exposure if they suspect drug use. In 2014, Tennessee became the first state to pass a “fetal assault” law specifically allowing prosecution of pregnant women who use drugs, imposing penalties of up to 15 years in prison. The legislation was so controversial it was discontinued in 2016, but has been introduced several times since.

Monitoring for drug use, however, happens disproportionately along racial lines. While white and Black birthing parents have similar rates of any drug use during the prenatal period (though the substances used and patterns of use may differ slightly), an often-cited study from 1990 found that Black birthing parents were 10 times more likely than their white counterparts to be reported to health authorities for their drug use.

Some states are actively working to correct these disparities, with mixed results. A 2015 study of California hospitals that adopted a protocol to monitor all birthing parents for prenatal substance use found that it did not impact child protective services reporting disparities.

New York has taken a different approach. In a testimony to the New York City Council from 2020, David Hansell, Commissioner of the New York City Administration for Children’s Services, stated that the agency had actively discouraged health professionals from making reports to them about a child or parent who tests positive for a substance if there is no negative impact on their well-being and instead make a referral to a service agency. While this could theoretically help level out racial differences, the question remains whether the service agencies would be equipped and trained to adequately address the physical and mental health and other needs of a birthing parent using substances.

Vermont has also taken steps to eliminate the reporting requirement for healthcare practitioners treating birthing parents using substances. If a birthing parent tests positive only for marijuana, they are exempt from hospitals’ and healthcare professionals’ reporting requirements to the Department of Children and Families (although if the marijuana use is thought to endanger a child, it must be reported). The marijuana-only exemption in Vermont is informed by the lack of sufficient evidence suggesting that marijuana use during pregnancy is harmful. But similarly, there is a lack of sufficient evidence demonstrating that other psychedelics are harmful.

For birthing parents who do test positive for substances, their risk of losing custody is also informed by structural racism within the child welfare system. According to Dr. Kelly Sykes, a psychedelic integration therapist and child forensic psychologist, disparities exist between legal systems that govern custody and child protection systems. Allegations of abuse, neglect and drug abuse requiring court intervention exist in both systems. However, only parents within the child protection system—which disproportionately impacts poor single parents of color—can have their parental rights terminated and be permanently banned from having contact with their child. Further, all aspects of their parental judgement are subject to scrutiny; they may be randomly tested for substances, regardless of whether substance abuse was a part of their child protection case.

Community support ~ Making decisions on psychedelics during pregnancy

In this landscape of inconclusive, biased and misleading information, how can birthing parents make informed decisions on this topic? And without information from peer-reviewed, evidence based research, what might drive someone to elect to use psychedelics all the same during their pregnancy?

For some birthing parents, the mental health benefits outweigh the potential risks.

“Psychedelics can reduce anxiety and depression, and can help people cope with dramatic changes in their lives,” said Fielding. “For those reasons, it’s certainly possible that psychedelics could be beneficial for expectant mothers struggling with prenatal depression or anxiety.”

Dolan, who has worked with pregnant people using cannabis to address treatment-resistant hyperemesis, a condition in pregnancy that creates severe and persistent nausea, frames the issue similarly. "If anxiety and stress impede on the connection between parent and baby, research shows that the relationship and connection is just as, if not more important than the little bit of pharmaceutical that’s going to pass through your breastmilk or pass through in utero to the child,” she says.

Being in a safe, supportive community to help weigh those decisions and process experiences in a nonjudgmental way can be very helpful. For someone like Pizano, this community is built into her everyday life. She grew up attending peyote ceremonies for occasions like baby namings, funerals or healing, and the wisdom she relies on comes from a long lineage of oral tradition, passed down by elders.

For those without such a cultural container, more options are emerging for pregnant people in need of support. A recent event on Clubhouse hosted by @mamadelamyco brought together doctors and consumers to speak about psychedelics and pregnancy. On Instagram, communities like @cannabisandparenthood and @bluntblowinmama explore this topic specifically with cannabis. Other groups like Plant Parenthood (which this writer founded) also bring together parents to speak about topics that are so stigmatized, they’re rarely spoken about with others.

“Obviously safety is still a primary concern when it comes to kids and psychedelics, let alone issues like pregnancy,” says Andrew Rose, who co-facilitates Plant Parenthood, “but the riskiest thing is not talking about it at all. You can’t have good healthy community education without open, non-judgmental communication.”

Without a clear path for more research on the horizon, and with a landscape of confusing information to draw from, birthing parents will likely struggle to find simple answers. Individuals will still need to factor in their own level of vulnerability, which varies greatly based on race and other socioeconomic and cultural factors. Perhaps the answers we seek do not exist within a search engine, but in a patchwork of wisdom from Western medical research, ancestral knowledge and most importantly, our own inner healing intelligence.

Rebecca-Kronman-Psychedelics-and-Pregnancy.jpg


Rebecca Kronman, LCSW is a licensed therapist and founder of Plant Parenthood, a digital and in-person community of parents who use psychedelics. She is also an assisting trainer with Fluence, a company that trains healthcare practitioners in harm reduction informed psychedelic preparation and integration. At her private practice in Brooklyn, she works with clients using mindfulness, experiential techniques and ketamine assisted psychotherapy to address depression, anxiety and life transitions. She also helps clients prepare for psychedelic experiences, incorporate insights or cope with challenges post-experience. Selected trainings include Mindfulness Based Stress Reduction, Mindfulness for Clinicians, Psychedelics 101 & 102 and Beyond Experience Psychedelic Integration Workshop. Outside of work, she is a mother of two boys ages 5 and 7.

 
Last edited:
Top